{"transactions":[{"id":811786,"issuer":{"id":6860,"kind":"organization","name":"Adicet Bio, Inc."},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53130,"kind":"organization","name":"OrbiMed Capital GP V LLC","position":2,"cik":"0001615374","reported_name":"OrbiMed Capital GP V LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51517,"kind":"person","name":"OrbiMed Capital GP VI LLC","position":3,"cik":"0001682115","reported_name":"OrbiMed Capital GP VI LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":4,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53131,"kind":"organization","name":"OrbiMed Advisors Israel II Ltd","position":5,"cik":"0001682093","reported_name":"OrbiMed Advisors Israel II Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53132,"kind":"organization","name":"OrbiMed Israel GP II, L.P.","position":6,"cik":"0001682090","reported_name":"OrbiMed Israel GP II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53133,"kind":"organization","name":"OrbiMed Israel GP Ltd.","position":7,"cik":"0001569590","reported_name":"OrbiMed Israel GP Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53134,"kind":"organization","name":"OrbiMed Israel BioFund GP Limited Partnership","position":8,"cik":"0001569821","reported_name":"OrbiMed Israel BioFund GP Limited Partnership","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-04-09T21:38:36.000Z","date":"2026-04-08","kind":"sale","planned":false,"acquired":false,"shares":40416,"price":6.52,"value":263512.32,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by OrbiMed Israel Partners II, L.P. (\"OIP II\"). OrbiMed Israel GP II, L.P. (\"OrbiMed Israel GP II\") is the general partner of OIP II, and OrbiMed Advisors Israel II Limited (\"OrbiMed Israel II\") is the general partner of OrbiMed Israel GP II. By virtue of such relationships, OrbiMed Israel GP II and OrbiMed Israel II may be deemed to have voting and investment power over the shares of common stock held by OIP II and, as a result, may be deemed to have beneficial ownership over such shares of common stock. OrbiMed Israel II exercises this investment and voting power through an investment committee comprised of Carl L. Gordon, David Bonita, and Erez Chimovits, each of whom disclaims beneficial ownership over the shares of common stock held by OIP II."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Each of OrbiMed Advisors, OrbiMed BioFund, OrbiMed Israel GP, OrbiMed Israel GP II, OrbiMed Israel II, Genesis GP, GP V, and GP VI disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of his or its pecuniary interest therein, if any. This report shall not be deemed an admission that any such person or entity is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000947871-26-000421","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787126000421/ownership.xml","form_type":"4"}},{"id":811785,"issuer":{"id":6860,"kind":"organization","name":"Adicet Bio, Inc."},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53130,"kind":"organization","name":"OrbiMed Capital GP V LLC","position":2,"cik":"0001615374","reported_name":"OrbiMed Capital GP V LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51517,"kind":"person","name":"OrbiMed Capital GP VI LLC","position":3,"cik":"0001682115","reported_name":"OrbiMed Capital GP VI LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":4,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53131,"kind":"organization","name":"OrbiMed Advisors Israel II Ltd","position":5,"cik":"0001682093","reported_name":"OrbiMed Advisors Israel II Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53132,"kind":"organization","name":"OrbiMed Israel GP II, L.P.","position":6,"cik":"0001682090","reported_name":"OrbiMed Israel GP II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53133,"kind":"organization","name":"OrbiMed Israel GP Ltd.","position":7,"cik":"0001569590","reported_name":"OrbiMed Israel GP Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53134,"kind":"organization","name":"OrbiMed Israel BioFund GP Limited Partnership","position":8,"cik":"0001569821","reported_name":"OrbiMed Israel BioFund GP Limited Partnership","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-04-09T21:38:36.000Z","date":"2026-04-08","kind":"sale","planned":false,"acquired":false,"shares":32523,"price":6.29,"value":204569.67,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These securities are held of record by OrbiMed Israel Partners Limited Partnership (\"OIP\"). OrbiMed Israel BioFund GP Limited Partnership (\"OrbiMed BioFund\") is the general partner of OIP, and OrbiMed Israel GP Ltd. (\"OrbiMed Israel GP\") is the general partner of OrbiMed BioFund. By virtue of such relationships, OrbiMed BioFund and OrbiMed Israel GP may be deemed to have voting and investment power over the shares of common stock held by OIP and, as a result, may be deemed to have beneficial ownership over such shares of common stock. OrbiMed Israel GP exercises this investment and voting power through an investment committee comprised of Carl L. Gordon and Erez Chimovits, each of whom disclaims beneficial ownership over the shares of common stock held by OIP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Each of OrbiMed Advisors, OrbiMed BioFund, OrbiMed Israel GP, OrbiMed Israel GP II, OrbiMed Israel II, Genesis GP, GP V, and GP VI disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of his or its pecuniary interest therein, if any. This report shall not be deemed an admission that any such person or entity is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000947871-26-000421","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787126000421/ownership.xml","form_type":"4"}},{"id":811784,"issuer":{"id":6860,"kind":"organization","name":"Adicet Bio, Inc."},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53130,"kind":"organization","name":"OrbiMed Capital GP V LLC","position":2,"cik":"0001615374","reported_name":"OrbiMed Capital GP V LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51517,"kind":"person","name":"OrbiMed Capital GP VI LLC","position":3,"cik":"0001682115","reported_name":"OrbiMed Capital GP VI LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":4,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53131,"kind":"organization","name":"OrbiMed Advisors Israel II Ltd","position":5,"cik":"0001682093","reported_name":"OrbiMed Advisors Israel II Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53132,"kind":"organization","name":"OrbiMed Israel GP II, L.P.","position":6,"cik":"0001682090","reported_name":"OrbiMed Israel GP II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53133,"kind":"organization","name":"OrbiMed Israel GP Ltd.","position":7,"cik":"0001569590","reported_name":"OrbiMed Israel GP Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53134,"kind":"organization","name":"OrbiMed Israel BioFund GP Limited Partnership","position":8,"cik":"0001569821","reported_name":"OrbiMed Israel BioFund GP Limited Partnership","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-04-09T21:38:36.000Z","date":"2026-04-07","kind":"sale","planned":false,"acquired":false,"shares":2400,"price":6.38,"value":15312.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These securities are held of record by OrbiMed Israel Partners Limited Partnership (\"OIP\"). OrbiMed Israel BioFund GP Limited Partnership (\"OrbiMed BioFund\") is the general partner of OIP, and OrbiMed Israel GP Ltd. (\"OrbiMed Israel GP\") is the general partner of OrbiMed BioFund. By virtue of such relationships, OrbiMed BioFund and OrbiMed Israel GP may be deemed to have voting and investment power over the shares of common stock held by OIP and, as a result, may be deemed to have beneficial ownership over such shares of common stock. OrbiMed Israel GP exercises this investment and voting power through an investment committee comprised of Carl L. Gordon and Erez Chimovits, each of whom disclaims beneficial ownership over the shares of common stock held by OIP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Each of OrbiMed Advisors, OrbiMed BioFund, OrbiMed Israel GP, OrbiMed Israel GP II, OrbiMed Israel II, Genesis GP, GP V, and GP VI disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of his or its pecuniary interest therein, if any. This report shall not be deemed an admission that any such person or entity is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":32523,"source":{"system":"sec-edgar","filing":"0000947871-26-000421","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787126000421/ownership.xml","form_type":"4"}},{"id":811783,"issuer":{"id":6860,"kind":"organization","name":"Adicet Bio, Inc."},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53130,"kind":"organization","name":"OrbiMed Capital GP V LLC","position":2,"cik":"0001615374","reported_name":"OrbiMed Capital GP V LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51517,"kind":"person","name":"OrbiMed Capital GP VI LLC","position":3,"cik":"0001682115","reported_name":"OrbiMed Capital GP VI LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":4,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53131,"kind":"organization","name":"OrbiMed Advisors Israel II Ltd","position":5,"cik":"0001682093","reported_name":"OrbiMed Advisors Israel II Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53132,"kind":"organization","name":"OrbiMed Israel GP II, L.P.","position":6,"cik":"0001682090","reported_name":"OrbiMed Israel GP II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53133,"kind":"organization","name":"OrbiMed Israel GP Ltd.","position":7,"cik":"0001569590","reported_name":"OrbiMed Israel GP Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53134,"kind":"organization","name":"OrbiMed Israel BioFund GP Limited Partnership","position":8,"cik":"0001569821","reported_name":"OrbiMed Israel BioFund GP Limited Partnership","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-04-09T21:38:36.000Z","date":"2026-04-07","kind":"sale","planned":false,"acquired":false,"shares":29319,"price":6.53,"value":191453.07,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These securities are held of record by OrbiMed Israel Partners Limited Partnership (\"OIP\"). OrbiMed Israel BioFund GP Limited Partnership (\"OrbiMed BioFund\") is the general partner of OIP, and OrbiMed Israel GP Ltd. (\"OrbiMed Israel GP\") is the general partner of OrbiMed BioFund. By virtue of such relationships, OrbiMed BioFund and OrbiMed Israel GP may be deemed to have voting and investment power over the shares of common stock held by OIP and, as a result, may be deemed to have beneficial ownership over such shares of common stock. OrbiMed Israel GP exercises this investment and voting power through an investment committee comprised of Carl L. Gordon and Erez Chimovits, each of whom disclaims beneficial ownership over the shares of common stock held by OIP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Each of OrbiMed Advisors, OrbiMed BioFund, OrbiMed Israel GP, OrbiMed Israel GP II, OrbiMed Israel II, Genesis GP, GP V, and GP VI disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of his or its pecuniary interest therein, if any. This report shall not be deemed an admission that any such person or entity is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":34923,"source":{"system":"sec-edgar","filing":"0000947871-26-000421","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787126000421/ownership.xml","form_type":"4"}},{"id":1013366,"issuer":{"id":7062,"kind":"organization","name":"PMV Pharmaceuticals, Inc.","symbol":"PMVP"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53130,"kind":"organization","name":"OrbiMed Capital GP V LLC","position":2,"cik":"0001615374","reported_name":"OrbiMed Capital GP V LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-10-27T21:19:23.000Z","date":"2025-10-23","kind":"sale","planned":false,"acquired":false,"shares":1000000,"price":1.52,"value":1520000.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These securities are held of record by OrbiMed Private Investments V, LP (\"OPI V\"). OrbiMed Capital GP V LLC (\"GP V\") is the general partner of OPI V, and OrbiMed Advisors LLC (\"OrbiMed Advisors\"), a registered investment advisor under the Investment Advisors Act of 1940, as amended, is the managing member of GP V. By virtue of such relationships, GP V and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by OPI V. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI V."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"This report on Form 4 is jointly filed by OrbiMed Advisors and GP V. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1943, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":4975291,"source":{"system":"sec-edgar","filing":"0000947871-25-000927","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787125000927/ownership.xml","form_type":"4"}},{"id":1020454,"issuer":{"id":6860,"kind":"organization","name":"Adicet Bio, Inc."},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53130,"kind":"organization","name":"OrbiMed Capital GP V LLC","position":2,"cik":"0001615374","reported_name":"OrbiMed Capital GP V LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51517,"kind":"person","name":"OrbiMed Capital GP VI LLC","position":3,"cik":"0001682115","reported_name":"OrbiMed Capital GP VI LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":4,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53131,"kind":"organization","name":"OrbiMed Advisors Israel II Ltd","position":5,"cik":"0001682093","reported_name":"OrbiMed Advisors Israel II Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53132,"kind":"organization","name":"OrbiMed Israel GP II, L.P.","position":6,"cik":"0001682090","reported_name":"OrbiMed Israel GP II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53133,"kind":"organization","name":"OrbiMed Israel GP Ltd.","position":7,"cik":"0001569590","reported_name":"OrbiMed Israel GP Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53134,"kind":"organization","name":"OrbiMed Israel BioFund GP Limited Partnership","position":8,"cik":"0001569821","reported_name":"OrbiMed Israel BioFund GP Limited Partnership","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-10-11T00:06:01.000Z","date":"2025-10-08","kind":"purchase","planned":false,"acquired":true,"shares":3500000,"price":1,"value":3500000.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These securities were purchased in an underwritten registered direct offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"These securities are held of record by OrbiMed Private Investments VI, LP (\"OPI VI\"). OrbiMed Capital GP VI LLC (\"GP VI\") is the general partner of OPI VI, and OrbiMed Advisors is the managing member of GP VI. By virtue of such relationships, GP VI and OrbiMed Advisors may be deemed to have voting and investment power over the shares of common stock held by OPI VI and, as a result, may be deemed to have beneficial ownership over such shares of common stock. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership over the shares of common stock held by OPI VI."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"Each of OrbiMed Advisors, OrbiMed BioFund, OrbiMed Israel GP, OrbiMed Israel GP II, OrbiMed Israel II, GP V, GP VI, and Genesis GP disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of his or its pecuniary interest therein, if any. This report shall not be deemed an admission that any such person or entity is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":4490254,"source":{"system":"sec-edgar","filing":"0000947871-25-000898","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787125000898/ownership.xml","form_type":"4"}},{"id":1020453,"issuer":{"id":6860,"kind":"organization","name":"Adicet Bio, Inc."},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53130,"kind":"organization","name":"OrbiMed Capital GP V LLC","position":2,"cik":"0001615374","reported_name":"OrbiMed Capital GP V LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51517,"kind":"person","name":"OrbiMed Capital GP VI LLC","position":3,"cik":"0001682115","reported_name":"OrbiMed Capital GP VI LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":4,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53131,"kind":"organization","name":"OrbiMed Advisors Israel II Ltd","position":5,"cik":"0001682093","reported_name":"OrbiMed Advisors Israel II Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53132,"kind":"organization","name":"OrbiMed Israel GP II, L.P.","position":6,"cik":"0001682090","reported_name":"OrbiMed Israel GP II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53133,"kind":"organization","name":"OrbiMed Israel GP Ltd.","position":7,"cik":"0001569590","reported_name":"OrbiMed Israel GP Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53134,"kind":"organization","name":"OrbiMed Israel BioFund GP Limited Partnership","position":8,"cik":"0001569821","reported_name":"OrbiMed Israel BioFund GP Limited Partnership","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-10-11T00:06:01.000Z","date":"2025-10-08","kind":"purchase","planned":false,"acquired":true,"shares":1500000,"price":1,"value":1500000.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These securities were purchased in an underwritten registered direct offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These securities are held of record by OrbiMed Private Investments V, LP (\"OPI V\"). OrbiMed Capital GP V LLC (\"GP V\") is the general partner of OPI V, and OrbiMed Advisors LLC (\"OrbiMed Advisors\"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the managing member of GP V. By virtue of such relationships, GP V and OrbiMed Advisors may be deemed to have voting and investment power over the shares of common stock held by OPI V and, as a result, may be deemed to have beneficial ownership over such shares of common stock. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership over the shares of common stock held by OPI V."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"Each of OrbiMed Advisors, OrbiMed BioFund, OrbiMed Israel GP, OrbiMed Israel GP II, OrbiMed Israel II, GP V, GP VI, and Genesis GP disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of his or its pecuniary interest therein, if any. This report shall not be deemed an admission that any such person or entity is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":9026359,"source":{"system":"sec-edgar","filing":"0000947871-25-000898","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787125000898/ownership.xml","form_type":"4"}},{"id":1041918,"issuer":{"id":7062,"kind":"organization","name":"PMV Pharmaceuticals, Inc.","symbol":"PMVP"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53130,"kind":"organization","name":"OrbiMed Capital GP V LLC","position":2,"cik":"0001615374","reported_name":"OrbiMed Capital GP V LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-09-12T21:09:08.000Z","date":"2025-09-10","kind":"sale","planned":false,"acquired":false,"shares":500000,"price":1.8,"value":900000.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These securities are held of record by OrbiMed Private Investments V, LP (\"OPI V\"). OrbiMed Capital GP V LLC (\"GP V\") is the general partner of OPI V, and OrbiMed Advisors LLC (\"OrbiMed Advisors\"), a registered investment advisor under the Investment Advisors Act of 1940, as amended, is the managing member of GP V. By virtue of such relationships, GP V and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by OPI V. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI V."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"This report on Form 4 is jointly filed by OrbiMed Advisors and GP V. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1943, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":5975291,"source":{"system":"sec-edgar","filing":"0000947871-25-000854","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787125000854/ownership.xml","form_type":"4"}},{"id":1098293,"issuer":{"id":4839,"kind":"organization","name":"Corvus Pharmaceuticals, Inc."},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53130,"kind":"organization","name":"OrbiMed Capital GP V LLC","position":2,"cik":"0001615374","reported_name":"OrbiMed Capital GP V LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Warrants (right to buy)","published_at":"2025-07-02T01:23:37.000Z","date":"2025-06-27","kind":"other","planned":false,"acquired":false,"shares":1397684,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by OPI V. OrbiMed Capital GP V LLC (\"GP V\") is the general partner of OPI V, and OrbiMed Advisors LLC (\"OrbiMed Advisors\"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the managing member of GP V. By virtue of such relationships, GP V and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by OPI V noted above and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"). OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI V."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"This report on Form 4 is jointly filed by OrbiMed Advisors and GP V. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1943, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors and GP V have designated a representative, Peter A. Thompson, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":0,"derivative":{"exercise_price":3.5,"exercise_date":"2025-04-29","expiration_date":"2025-06-30","underlying":"Common Stock","underlying_shares":1397684},"source":{"system":"sec-edgar","filing":"0000947871-25-000636","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787125000636/ownership.xml","form_type":"4"}},{"id":1098292,"issuer":{"id":4839,"kind":"organization","name":"Corvus Pharmaceuticals, Inc."},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53130,"kind":"organization","name":"OrbiMed Capital GP V LLC","position":2,"cik":"0001615374","reported_name":"OrbiMed Capital GP V LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-07-02T01:23:37.000Z","date":"2025-06-27","kind":"sale","planned":false,"acquired":false,"shares":1176332,"price":4.1586,"value":4891894.2552,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On June 27, 2025, OrbiMed Private Investments V, LP (\"OPI V\") exercised common warrants (\"Warrants\") to purchase 1,397,684 shares of the Issuer's Common Stock for $3.50 per share. OPI V paid the exercise price on a cashless basis, resulting in the Issuer withholding 1,176,332 of the Warrant shares to pay the exercise price and issuing to OPI V the remaining 221,352 shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by OPI V. OrbiMed Capital GP V LLC (\"GP V\") is the general partner of OPI V, and OrbiMed Advisors LLC (\"OrbiMed Advisors\"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the managing member of GP V. By virtue of such relationships, GP V and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by OPI V noted above and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"). OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI V."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"This report on Form 4 is jointly filed by OrbiMed Advisors and GP V. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1943, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors and GP V have designated a representative, Peter A. Thompson, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":7165006,"source":{"system":"sec-edgar","filing":"0000947871-25-000636","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787125000636/ownership.xml","form_type":"4"}},{"id":1098291,"issuer":{"id":4839,"kind":"organization","name":"Corvus Pharmaceuticals, Inc."},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53130,"kind":"organization","name":"OrbiMed Capital GP V LLC","position":2,"cik":"0001615374","reported_name":"OrbiMed Capital GP V LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-07-02T01:23:37.000Z","date":"2025-06-27","kind":"other","planned":false,"acquired":true,"shares":1397684,"price":3.5,"value":4891894.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by OPI V. OrbiMed Capital GP V LLC (\"GP V\") is the general partner of OPI V, and OrbiMed Advisors LLC (\"OrbiMed Advisors\"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the managing member of GP V. By virtue of such relationships, GP V and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by OPI V noted above and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"). OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI V."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"This report on Form 4 is jointly filed by OrbiMed Advisors and GP V. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1943, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors and GP V have designated a representative, Peter A. Thompson, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":8341338,"source":{"system":"sec-edgar","filing":"0000947871-25-000636","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787125000636/ownership.xml","form_type":"4"}},{"id":1523649,"issuer":{"id":4839,"kind":"organization","name":"Corvus Pharmaceuticals, Inc."},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53130,"kind":"organization","name":"OrbiMed Capital GP V LLC","position":2,"cik":"0001615374","reported_name":"OrbiMed Capital GP V LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Warrants (right to buy)","published_at":"2024-05-09T00:28:59.000Z","date":"2024-05-06","kind":"purchase","planned":false,"acquired":true,"shares":1397684,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Issued at no additional consideration to OPI V in connection with its subscription of Pre-Funded Warrants for shares of the Issuer's Common Stock at a price of $1.7311."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Subject to the terms and conditions set forth in the Common Warrant, the holder thereof may, at any time and from time to time on or after May 6, 2024, exercise the Common Warrant until it has been exercised in full. The Common Warrants reported herein contain an exercise limitation prohibiting the holder from exercising the Common Warrants until such time as the holder, together with the Reporting Persons and certain other related parties, would not beneficially own after any such exercise more than 9.99% of the then issued and outstanding Common Stock (the \"Blocker\"). Due to the Blocker, the Common Warrants beneficially owned by the Reporting Persons are not presently exercisable."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Subject to the terms and conditions set forth in the Common Warrant, the holder thereof may, at any time and from time to time on or after May 6, 2024, exercise the Common Warrant until it has been exercised in full. The Common Warrants reported herein contain an exercise limitation prohibiting the holder from exercising the Common Warrants until such time as the holder, together with the Reporting Persons and certain other related parties, would not beneficially own after any such exercise more than 9.99% of the then issued and outstanding Common Stock (the \"Blocker\"). Due to the Blocker, the Common Warrants beneficially owned by the Reporting Persons are not presently exercisable."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held of record by OrbiMed Private Investments V, LP (\"OPI V\"). OrbiMed Capital GP V LLC (\"GP V\") is the general partner of OPI V, and OrbiMed Advisors LLC (\"OrbiMed Advisors\"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the managing member of GP V. By virtue of such relationships, GP V and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by OPI V noted above and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"). OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI V."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"This report on Form 4 is jointly filed by OrbiMed Advisors and GP V. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1943, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors and GP V have designated a representative, Peter A. Thompson, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":1397684,"derivative":{"exercise_price":3.5,"underlying":"Common Stock","underlying_shares":1397684},"source":{"system":"sec-edgar","filing":"0000947871-24-000450","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787124000450/ownership.xml","form_type":"4"}},{"id":1523648,"issuer":{"id":4839,"kind":"organization","name":"Corvus Pharmaceuticals, Inc."},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53130,"kind":"organization","name":"OrbiMed Capital GP V LLC","position":2,"cik":"0001615374","reported_name":"OrbiMed Capital GP V LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Pre-Funded Warrants (right to buy)","published_at":"2024-05-09T00:28:59.000Z","date":"2024-05-06","kind":"purchase","planned":false,"acquired":true,"shares":1444085,"price":1.7311,"value":2499855.5435,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Subject to the terms and conditions set forth in the Pre-Funded Warrant, the holder thereof may, at any time and from time to time on or after May 6, 2024, exercise the Pre-Funded Warrant until it has been exercised in full. The Pre-Funded Warrants reported herein contain an exercise limitation prohibiting the holder from exercising the Pre-Funded Warrants until such time as the holder, together with the Reporting Persons and certain other related parties, would not beneficially own after any such exercise more than 9.99% of the then issued and outstanding Common Stock (the \"Blocker\"). Due to the Blocker, the Pre-Funded Warrants beneficially owned by the Reporting Persons are not presently exercisable."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Subject to the terms and conditions set forth in the Pre-Funded Warrant, the holder thereof may, at any time and from time to time on or after May 6, 2024, exercise the Pre-Funded Warrant until it has been exercised in full. The Pre-Funded Warrants reported herein contain an exercise limitation prohibiting the holder from exercising the Pre-Funded Warrants until such time as the holder, together with the Reporting Persons and certain other related parties, would not beneficially own after any such exercise more than 9.99% of the then issued and outstanding Common Stock (the \"Blocker\"). Due to the Blocker, the Pre-Funded Warrants beneficially owned by the Reporting Persons are not presently exercisable."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held of record by OrbiMed Private Investments V, LP (\"OPI V\"). OrbiMed Capital GP V LLC (\"GP V\") is the general partner of OPI V, and OrbiMed Advisors LLC (\"OrbiMed Advisors\"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the managing member of GP V. By virtue of such relationships, GP V and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by OPI V noted above and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"). OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI V."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"This report on Form 4 is jointly filed by OrbiMed Advisors and GP V. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1943, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors and GP V have designated a representative, Peter A. Thompson, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":1444085,"derivative":{"exercise_price":0.0001,"underlying":"Common Stock","underlying_shares":1444085},"source":{"system":"sec-edgar","filing":"0000947871-24-000450","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787124000450/ownership.xml","form_type":"4"}},{"id":1669923,"issuer":{"id":6860,"kind":"organization","name":"Adicet Bio, Inc."},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53130,"kind":"organization","name":"OrbiMed Capital GP V LLC","position":2,"cik":"0001615374","reported_name":"OrbiMed Capital GP V LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51517,"kind":"person","name":"OrbiMed Capital GP VI LLC","position":3,"cik":"0001682115","reported_name":"OrbiMed Capital GP VI LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":4,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53131,"kind":"organization","name":"OrbiMed Advisors Israel II Ltd","position":5,"cik":"0001682093","reported_name":"OrbiMed Advisors Israel II Ltd","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53132,"kind":"organization","name":"OrbiMed Israel GP II, L.P.","position":6,"cik":"0001682090","reported_name":"OrbiMed Israel GP II, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53133,"kind":"organization","name":"OrbiMed Israel GP Ltd.","position":7,"cik":"0001569590","reported_name":"OrbiMed Israel GP Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53134,"kind":"organization","name":"OrbiMed Israel BioFund GP Limited Partnership","position":8,"cik":"0001569821","reported_name":"OrbiMed Israel BioFund GP Limited Partnership","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-01-27T00:14:22.000Z","date":"2024-01-25","kind":"purchase","planned":false,"acquired":true,"shares":1041700,"price":2.4,"value":2500080.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares of the Issuer's common stock were purchased in the Issuer's underwritten public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"This report is being jointly filed by OrbiMed Advisors, GP V, GP VI, Genesis GP, OrbiMed Israel GP II, OrbiMed Israel II, OrbiMed BioFund, and OrbiMed Israel GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors, GP V, GP VI, OrbiMed Israel GP II, OrbiMed Israel II, OrbiMed BioFund, and OrbiMed Israel GP have designated Carl L. Gordon (\"Gordon\") to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Persons or Gordon is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"These shares of the Issuer's common stock are held of record by OrbiMed Genesis Master Fund, L.P. (\"Genesis\"). OrbiMed Genesis GP LLC (\"Genesis GP\") is the general partner of Genesis, and OrbiMed Advisors is the managing member of Genesis. By virtue of such relationships, Genesis GP and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by Genesis noted above and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Exchange Act. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the Shares held by Genesis."}],"balance_after":1255985,"source":{"system":"sec-edgar","filing":"0000950170-24-008053","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000095017024008053/ownership.xml","form_type":"4"}},{"id":1669922,"issuer":{"id":6860,"kind":"organization","name":"Adicet Bio, Inc."},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53130,"kind":"organization","name":"OrbiMed Capital GP V LLC","position":2,"cik":"0001615374","reported_name":"OrbiMed Capital GP V LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51517,"kind":"person","name":"OrbiMed Capital GP VI LLC","position":3,"cik":"0001682115","reported_name":"OrbiMed Capital GP VI LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":4,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53131,"kind":"organization","name":"OrbiMed Advisors Israel II Ltd","position":5,"cik":"0001682093","reported_name":"OrbiMed Advisors Israel II Ltd","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53132,"kind":"organization","name":"OrbiMed Israel GP II, L.P.","position":6,"cik":"0001682090","reported_name":"OrbiMed Israel GP II, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53133,"kind":"organization","name":"OrbiMed Israel GP Ltd.","position":7,"cik":"0001569590","reported_name":"OrbiMed Israel GP Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53134,"kind":"organization","name":"OrbiMed Israel BioFund GP Limited Partnership","position":8,"cik":"0001569821","reported_name":"OrbiMed Israel BioFund GP Limited Partnership","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-01-27T00:14:22.000Z","date":"2024-01-25","kind":"purchase","planned":false,"acquired":true,"shares":242200,"price":2.4,"value":581280.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares of the Issuer's common stock were purchased in the Issuer's underwritten public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"This report is being jointly filed by OrbiMed Advisors, GP V, GP VI, Genesis GP, OrbiMed Israel GP II, OrbiMed Israel II, OrbiMed BioFund, and OrbiMed Israel GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors, GP V, GP VI, OrbiMed Israel GP II, OrbiMed Israel II, OrbiMed BioFund, and OrbiMed Israel GP have designated Carl L. Gordon (\"Gordon\") to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Persons or Gordon is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These shares of the Issuer's common stock are held of record by OrbiMed Private Investments VI, LP (\"OPI VI\"). OrbiMed Capital GP VI LLC (\"GP VI\") is the general partner of OPI VI, and OrbiMed Advisors is the managing member of GP VI. By virtue of such relationships, GP VI and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by OPI VI noted above and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Exchange Act. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the Shares held by OPI VI."}],"balance_after":990254,"source":{"system":"sec-edgar","filing":"0000950170-24-008053","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000095017024008053/ownership.xml","form_type":"4"}},{"id":1669921,"issuer":{"id":6860,"kind":"organization","name":"Adicet Bio, Inc."},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53130,"kind":"organization","name":"OrbiMed Capital GP V LLC","position":2,"cik":"0001615374","reported_name":"OrbiMed Capital GP V LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51517,"kind":"person","name":"OrbiMed Capital GP VI LLC","position":3,"cik":"0001682115","reported_name":"OrbiMed Capital GP VI LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":4,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53131,"kind":"organization","name":"OrbiMed Advisors Israel II Ltd","position":5,"cik":"0001682093","reported_name":"OrbiMed Advisors Israel II Ltd","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53132,"kind":"organization","name":"OrbiMed Israel GP II, L.P.","position":6,"cik":"0001682090","reported_name":"OrbiMed Israel GP II, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53133,"kind":"organization","name":"OrbiMed Israel GP Ltd.","position":7,"cik":"0001569590","reported_name":"OrbiMed Israel GP Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53134,"kind":"organization","name":"OrbiMed Israel BioFund GP Limited Partnership","position":8,"cik":"0001569821","reported_name":"OrbiMed Israel BioFund GP Limited Partnership","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-01-27T00:14:22.000Z","date":"2024-01-25","kind":"purchase","planned":false,"acquired":true,"shares":1841100,"price":2.4,"value":4418640.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares of the Issuer's common stock were purchased in the Issuer's underwritten public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares of the Issuer's common stock are held of record by OrbiMed Private Investments V, LP (\"OPI V\"). OrbiMed Capital GP V LLC (\"GP V\") is the general partner of OPI V, and OrbiMed Advisors LLC (\"OrbiMed Advisors\"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the managing member of GP V. By virtue of such relationships, GP V and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by OPI V noted above and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"). OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI V."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"This report is being jointly filed by OrbiMed Advisors, GP V, GP VI, Genesis GP, OrbiMed Israel GP II, OrbiMed Israel II, OrbiMed BioFund, and OrbiMed Israel GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors, GP V, GP VI, OrbiMed Israel GP II, OrbiMed Israel II, OrbiMed BioFund, and OrbiMed Israel GP have designated Carl L. Gordon (\"Gordon\") to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Persons or Gordon is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":7526359,"source":{"system":"sec-edgar","filing":"0000950170-24-008053","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000095017024008053/ownership.xml","form_type":"4"}},{"id":1730498,"issuer":{"id":7062,"kind":"organization","name":"PMV Pharmaceuticals, Inc.","symbol":"PMVP"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53130,"kind":"organization","name":"OrbiMed Capital GP V LLC","position":2,"cik":"0001615374","reported_name":"OrbiMed Capital GP V LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":3,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-11-24T21:38:04.000Z","date":"2023-11-22","kind":"sale","planned":false,"acquired":false,"shares":87786,"price":2.23,"value":195762.78,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These securities are held of record by OrbiMed Genesis Master Fund, L.P. (\"Genesis Master Fund\"). OrbiMed Genesis GP LLC (\"Genesis GP\") is the general partner of Genesis Master Fund and OrbiMed Advisors LLC (\"OrbiMed Advisors\"), a registered investment advisor under the Investment Advisors Act of 1940, as amended, is the managing member of Genesis GP. By virtue of such relationships, Genesis GP and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by Genesis Master Fund. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by Genesis Master Fund."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"This report on Form 4 is jointly filed by OrbiMed Advisors, GP V and Genesis GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1943, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000947871-23-001104","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787123001104/ownership.xml","form_type":"4"}},{"id":1842241,"issuer":{"id":6860,"kind":"organization","name":"Adicet Bio, Inc."},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53130,"kind":"organization","name":"OrbiMed Capital GP V LLC","position":2,"cik":"0001615374","reported_name":"OrbiMed Capital GP V LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51517,"kind":"person","name":"OrbiMed Capital GP VI LLC","position":3,"cik":"0001682115","reported_name":"OrbiMed Capital GP VI LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":4,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53131,"kind":"organization","name":"OrbiMed Advisors Israel II Ltd","position":5,"cik":"0001682093","reported_name":"OrbiMed Advisors Israel II Ltd","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53132,"kind":"organization","name":"OrbiMed Israel GP II, L.P.","position":6,"cik":"0001682090","reported_name":"OrbiMed Israel GP II, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53133,"kind":"organization","name":"OrbiMed Israel GP Ltd.","position":7,"cik":"0001569590","reported_name":"OrbiMed Israel GP Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53134,"kind":"organization","name":"OrbiMed Israel BioFund GP Limited Partnership","position":8,"cik":"0001569821","reported_name":"OrbiMed Israel BioFund GP Limited Partnership","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24622,"kind":"person","name":"Chimovits Erez","position":9,"cik":"0001706399","reported_name":"Chimovits Erez","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-06-29T20:46:01.000Z","date":"2023-06-27","kind":"purchase","planned":false,"acquired":true,"shares":58000,"price":2.09,"value":121220.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents the weighted average purchase price of the shares of common stock purchased, ranging from a low of $2.08 to a high of $2.12 per share. The Reporting Persons undertake, upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, to provide full information regarding the number of shares purchased at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"These shares of the Issuer's common stock are held of record by OrbiMed Private Investments VI, LP (\"OPI VI\"). OrbiMed Capital GP VI LLC (\"GP VI\") is the general partner of OPI VI, and OrbiMed Advisors is the managing member of GP VI. By virtue of such relationships, GP VI and OrbiMed Advisors may be deemed to have voting and investment power over the shares of common stock held by OPI VI and, as a result, may be deemed to have beneficial ownership over such shares of common stock. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership over the shares of common stock held by OPI VI."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"Each of OrbiMed Advisors, OrbiMed BioFund, OrbiMed Israel GP, OrbiMed Israel GP II, OrbiMed Israel II, GP V, GP VI, Genesis GP, and Erez Chimovits disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of his or its pecuniary interest therein, if any. OrbiMed Advisors, GP V and GP VI have designated a representative, Carl L. Gordon, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such person or entity is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":748054,"source":{"system":"sec-edgar","filing":"0000947871-23-000713","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787123000713/ownership.xml","form_type":"4"}},{"id":1842240,"issuer":{"id":6860,"kind":"organization","name":"Adicet Bio, Inc."},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53130,"kind":"organization","name":"OrbiMed Capital GP V LLC","position":2,"cik":"0001615374","reported_name":"OrbiMed Capital GP V LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51517,"kind":"person","name":"OrbiMed Capital GP VI LLC","position":3,"cik":"0001682115","reported_name":"OrbiMed Capital GP VI LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":4,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53131,"kind":"organization","name":"OrbiMed Advisors Israel II Ltd","position":5,"cik":"0001682093","reported_name":"OrbiMed Advisors Israel II Ltd","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53132,"kind":"organization","name":"OrbiMed Israel GP II, L.P.","position":6,"cik":"0001682090","reported_name":"OrbiMed Israel GP II, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53133,"kind":"organization","name":"OrbiMed Israel GP Ltd.","position":7,"cik":"0001569590","reported_name":"OrbiMed Israel GP Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53134,"kind":"organization","name":"OrbiMed Israel BioFund GP Limited Partnership","position":8,"cik":"0001569821","reported_name":"OrbiMed Israel BioFund GP Limited Partnership","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24622,"kind":"person","name":"Chimovits Erez","position":9,"cik":"0001706399","reported_name":"Chimovits Erez","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-06-29T20:46:01.000Z","date":"2023-06-27","kind":"purchase","planned":false,"acquired":true,"shares":442000,"price":2.09,"value":923780.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents the weighted average purchase price of the shares of common stock purchased, ranging from a low of $2.08 to a high of $2.12 per share. The Reporting Persons undertake, upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, to provide full information regarding the number of shares purchased at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These shares of the Issuer's common stock are held of record by OrbiMed Private Investments V, LP (\"OPI V\"). OrbiMed Capital GP V LLC (\"GP V\") is the general partner of OPI V, and OrbiMed Advisors LLC (\"OrbiMed Advisors\"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the managing member of GP V. By virtue of such relationships, GP V and OrbiMed Advisors may be deemed to have voting and investment power over the shares of common stock held by OPI V and, as a result, may be deemed to have beneficial ownership over such shares of common stock. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership over the shares of common stock held by OPI V."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"Each of OrbiMed Advisors, OrbiMed BioFund, OrbiMed Israel GP, OrbiMed Israel GP II, OrbiMed Israel II, GP V, GP VI, Genesis GP, and Erez Chimovits disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of his or its pecuniary interest therein, if any. OrbiMed Advisors, GP V and GP VI have designated a representative, Carl L. Gordon, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such person or entity is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":5685259,"source":{"system":"sec-edgar","filing":"0000947871-23-000713","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787123000713/ownership.xml","form_type":"4"}},{"id":1842239,"issuer":{"id":6860,"kind":"organization","name":"Adicet Bio, Inc."},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53130,"kind":"organization","name":"OrbiMed Capital GP V LLC","position":2,"cik":"0001615374","reported_name":"OrbiMed Capital GP V LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51517,"kind":"person","name":"OrbiMed Capital GP VI LLC","position":3,"cik":"0001682115","reported_name":"OrbiMed Capital GP VI LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":4,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53131,"kind":"organization","name":"OrbiMed Advisors Israel II Ltd","position":5,"cik":"0001682093","reported_name":"OrbiMed Advisors Israel II Ltd","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53132,"kind":"organization","name":"OrbiMed Israel GP II, L.P.","position":6,"cik":"0001682090","reported_name":"OrbiMed Israel GP II, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53133,"kind":"organization","name":"OrbiMed Israel GP Ltd.","position":7,"cik":"0001569590","reported_name":"OrbiMed Israel GP Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53134,"kind":"organization","name":"OrbiMed Israel BioFund GP Limited Partnership","position":8,"cik":"0001569821","reported_name":"OrbiMed Israel BioFund GP Limited Partnership","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24622,"kind":"person","name":"Chimovits Erez","position":9,"cik":"0001706399","reported_name":"Chimovits Erez","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-06-29T20:46:01.000Z","date":"2023-06-27","kind":"purchase","planned":false,"acquired":true,"shares":250000,"price":2.09,"value":522500.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents the weighted average purchase price of the shares of common stock purchased, ranging from a low of $2.08 to a high of $2.12 per share. The Reporting Persons undertake, upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, to provide full information regarding the number of shares purchased at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These shares of the Issuer's common stock are held of record by OrbiMed Israel Partners II, L.P. (\"OIP II\"). OrbiMed Israel GP II, L.P. (\"OrbiMed Israel GP II\") is the general partner of OIP II, and OrbiMed Advisors Israel II Limited (\"OrbiMed Israel II\") is the general partner of OrbiMed Israel GP II. By virtue of such relationships, OrbiMed Israel GP II and OrbiMed Israel II may be deemed to have voting and investment power over the shares of common stock held by OIP II and, as a result, may be deemed to have beneficial ownership over such shares of common stock. OrbiMed Israel II exercises this investment and voting power through an investment committee comprised of Carl L. Gordon, David Bonita, and Erez Chimovits, each of whom disclaims beneficial ownership over the shares of common stock held by OIP II."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"Each of OrbiMed Advisors, OrbiMed BioFund, OrbiMed Israel GP, OrbiMed Israel GP II, OrbiMed Israel II, GP V, GP VI, Genesis GP, and Erez Chimovits disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of his or its pecuniary interest therein, if any. OrbiMed Advisors, GP V and GP VI have designated a representative, Carl L. Gordon, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such person or entity is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":646657,"source":{"system":"sec-edgar","filing":"0000947871-23-000713","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787123000713/ownership.xml","form_type":"4"}},{"id":1842238,"issuer":{"id":6860,"kind":"organization","name":"Adicet Bio, Inc."},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53130,"kind":"organization","name":"OrbiMed Capital GP V LLC","position":2,"cik":"0001615374","reported_name":"OrbiMed Capital GP V LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51517,"kind":"person","name":"OrbiMed Capital GP VI LLC","position":3,"cik":"0001682115","reported_name":"OrbiMed Capital GP VI LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":4,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53131,"kind":"organization","name":"OrbiMed Advisors Israel II Ltd","position":5,"cik":"0001682093","reported_name":"OrbiMed Advisors Israel II Ltd","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53132,"kind":"organization","name":"OrbiMed Israel GP II, L.P.","position":6,"cik":"0001682090","reported_name":"OrbiMed Israel GP II, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53133,"kind":"organization","name":"OrbiMed Israel GP Ltd.","position":7,"cik":"0001569590","reported_name":"OrbiMed Israel GP Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53134,"kind":"organization","name":"OrbiMed Israel BioFund GP Limited Partnership","position":8,"cik":"0001569821","reported_name":"OrbiMed Israel BioFund GP Limited Partnership","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24622,"kind":"person","name":"Chimovits Erez","position":9,"cik":"0001706399","reported_name":"Chimovits Erez","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-06-29T20:46:01.000Z","date":"2023-06-27","kind":"purchase","planned":false,"acquired":true,"shares":125000,"price":2.09,"value":261250.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents the weighted average purchase price of the shares of common stock purchased, ranging from a low of $2.08 to a high of $2.12 per share. The Reporting Persons undertake, upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, to provide full information regarding the number of shares purchased at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares of the Issuer's common stock are held of record by OrbiMed Israel Partners Limited Partnership (\"OIP\"). OrbiMed Israel BioFund GP Limited Partnership (\"OrbiMed BioFund\") is the general partner of OIP, and OrbiMed Israel GP Ltd. (\"OrbiMed Israel GP\") is the general partner of OrbiMed BioFund. By virtue of such relationships, OrbiMed BioFund and OrbiMed Israel GP may be deemed to have voting and investment power over the shares of common stock held by OIP and, as a result, may be deemed to have beneficial ownership over such shares of common stock. OrbiMed Israel GP exercises this investment and voting power through an investment committee comprised of Carl L. Gordon and Erez Chimovits, each of whom disclaims beneficial ownership over the shares of common stock held by OIP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"Each of OrbiMed Advisors, OrbiMed BioFund, OrbiMed Israel GP, OrbiMed Israel GP II, OrbiMed Israel II, GP V, GP VI, Genesis GP, and Erez Chimovits disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of his or its pecuniary interest therein, if any. OrbiMed Advisors, GP V and GP VI have designated a representative, Carl L. Gordon, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such person or entity is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":1027885,"source":{"system":"sec-edgar","filing":"0000947871-23-000713","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787123000713/ownership.xml","form_type":"4"}},{"id":2104542,"issuer":{"id":122050,"kind":"organization","name":"Tricida, Inc.","symbol":"TCDA"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53130,"kind":"organization","name":"OrbiMed Capital GP V LLC","position":2,"cik":"0001615374","reported_name":"OrbiMed Capital GP V LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-11-26T01:13:12.000Z","date":"2022-11-25","kind":"sale","acquired":false,"shares":3629226,"price":0.22,"value":798429.72,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Shares are held of record by OrbiMed Private Investments V, LP (\"OPI V\"). OrbiMed Capital GP V LLC (\"GP V\") is the general partner of OPI V, and OrbiMed Advisors LLC (\"OrbiMed Advisors\"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the managing member of GP V. By virtue of such relationships, GP V and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by OPI V. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the Shares held by OPI V."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"This report on Form 4 is jointly filed by GP V and OrbiMed Advisors. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors and GP V have designated David Bonita (\"Bonita\"), a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Persons, or Bonita, is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000947871-22-001208","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787122001208/ownership.xml","form_type":"4"}},{"id":2104541,"issuer":{"id":122050,"kind":"organization","name":"Tricida, Inc.","symbol":"TCDA"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53130,"kind":"organization","name":"OrbiMed Capital GP V LLC","position":2,"cik":"0001615374","reported_name":"OrbiMed Capital GP V LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-11-26T01:13:12.000Z","date":"2022-11-23","kind":"sale","acquired":false,"shares":5617300,"price":0.21,"value":1179633.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Shares are held of record by OrbiMed Private Investments V, LP (\"OPI V\"). OrbiMed Capital GP V LLC (\"GP V\") is the general partner of OPI V, and OrbiMed Advisors LLC (\"OrbiMed Advisors\"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the managing member of GP V. By virtue of such relationships, GP V and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by OPI V. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the Shares held by OPI V."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"This report on Form 4 is jointly filed by GP V and OrbiMed Advisors. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors and GP V have designated David Bonita (\"Bonita\"), a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Persons, or Bonita, is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":3629226,"source":{"system":"sec-edgar","filing":"0000947871-22-001208","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787122001208/ownership.xml","form_type":"4"}},{"id":2104540,"issuer":{"id":122050,"kind":"organization","name":"Tricida, Inc.","symbol":"TCDA"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53130,"kind":"organization","name":"OrbiMed Capital GP V LLC","position":2,"cik":"0001615374","reported_name":"OrbiMed Capital GP V LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-11-26T01:13:12.000Z","date":"2022-11-22","kind":"sale","acquired":false,"shares":1034421,"price":0.22,"value":227572.62,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents the weighted average sale price of the shares of the Issuer's common stock (\"Shares\") sold, ranging from a low of $0.21 to a high of $0.22 per Share. The Reporting Persons undertake, upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, to provide full information regarding the number of Shares sold at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Shares are held of record by OrbiMed Private Investments V, LP (\"OPI V\"). OrbiMed Capital GP V LLC (\"GP V\") is the general partner of OPI V, and OrbiMed Advisors LLC (\"OrbiMed Advisors\"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the managing member of GP V. By virtue of such relationships, GP V and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by OPI V. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the Shares held by OPI V."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"This report on Form 4 is jointly filed by GP V and OrbiMed Advisors. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors and GP V have designated David Bonita (\"Bonita\"), a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Persons, or Bonita, is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":9246526,"source":{"system":"sec-edgar","filing":"0000947871-22-001208","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787122001208/ownership.xml","form_type":"4"}},{"id":2120274,"issuer":{"id":5614,"kind":"organization","name":"Compass Therapeutics, Inc.","symbol":"CMPX"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53130,"kind":"organization","name":"OrbiMed Capital GP V LLC","position":2,"cik":"0001615374","reported_name":"OrbiMed Capital GP V LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":3,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-11-10T21:44:21.000Z","date":"2022-11-08","kind":"purchase","acquired":true,"shares":402000,"price":3.21,"value":1290420.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares of the Issuer's common stock (\"Shares\") were purchased in a private placement exempt from the registration requirements of the Securities Act of 1933, as amended."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Shares are held of record by OrbiMed Private Investments V - KA, LP (\"OPI V-KA\"). OrbiMed Capital GP V LLC (\"GP V\") is the general partner of OPI V-KA, and OrbiMed Advisors LLC (\"OrbiMed Advisors\"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the managing member of GP V. By virtue of such relationships, GP V and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by OPI V-KA. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the Shares held by OPI V-KA."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"This report on Form 4 is jointly filed by GP V, OrbiMed Advisors, and Genesis GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors and GP V have designated Carl L. Gordon (\"Gordon\"), a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Persons, or Gordon, is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":15219994,"source":{"system":"sec-edgar","filing":"0000947871-22-001164","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787122001164/ownership.xml","form_type":"4"}},{"id":2251886,"issuer":{"id":7062,"kind":"organization","name":"PMV Pharmaceuticals, Inc.","symbol":"PMVP"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53130,"kind":"organization","name":"OrbiMed Capital GP V LLC","position":2,"cik":"0001615374","reported_name":"OrbiMed Capital GP V LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":3,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-05-31T20:36:35.000Z","date":"2022-05-26","kind":"sale","acquired":false,"shares":26253,"price":15.93,"value":418210.29,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the sale of shares of the Issuer's common stock (\"Shares\"), which was effected after market close on May 26, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"These Shares were sold in multiple transactions at prices ranging from $15.55 to $16.09. The price reported reflects the weighted average sale price. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Shares purchased at each separate price within the ranges set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Shares are held of record by OrbiMed Genesis Master Fund, L.P. (\"Genesis Master Fund\"). OrbiMed Genesis GP LLC (\"Genesis GP\") is the general partner of Genesis Master Fund and OrbiMed Advisors LLC (\"OrbiMed Advisors\"), a registered investment advisor under the Investment Advisors Act of 1940, as amended, is the managing member of Genesis GP. By virtue of such relationships, Genesis GP and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by Genesis Master Fund. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by Genesis Master Fund."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"This report on Form 4 is jointly filed by OrbiMed Advisors, GP V and Genesis GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1943, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":87786,"source":{"system":"sec-edgar","filing":"0000947871-22-000675","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787122000675/ownership.xml","form_type":"4"}},{"id":2272465,"issuer":{"id":5614,"kind":"organization","name":"Compass Therapeutics, Inc.","symbol":"CMPX"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53130,"kind":"organization","name":"OrbiMed Capital GP V LLC","position":2,"cik":"0001615374","reported_name":"OrbiMed Capital GP V LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":3,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-05-13T21:45:38.000Z","date":"2022-05-13","kind":"purchase","acquired":true,"shares":30722,"price":2.49,"value":76497.78,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"These Shares were purchased in multiple transactions at prices ranging from $2.46 to $2.54. The price reported reflects the weighted average purchase price. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Shares purchased at each separate price within the ranges set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The Shares are held of record by OrbiMed Private Investments V - KA, LP (\"OPI V-KA\"). OrbiMed Capital GP V LLC (\"GP V\") is the general partner of OPI V-KA, and OrbiMed Advisors LLC (\"OrbiMed Advisors\"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the managing member of GP V. By virtue of such relationships, GP V and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by OPI V-KA. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the Shares held by OPI V-KA."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"This report on Form 4 is jointly filed by GP V, OrbiMed Advisors, and Genesis GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors and GP V have designated Carl L. Gordon (\"Gordon\"), a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Persons, or Gordon, is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":14817994,"source":{"system":"sec-edgar","filing":"0000947871-22-000567","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787122000567/ownership.xml","form_type":"4"}},{"id":2272464,"issuer":{"id":5614,"kind":"organization","name":"Compass Therapeutics, Inc.","symbol":"CMPX"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53130,"kind":"organization","name":"OrbiMed Capital GP V LLC","position":2,"cik":"0001615374","reported_name":"OrbiMed Capital GP V LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":3,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-05-13T21:45:38.000Z","date":"2022-05-12","kind":"purchase","acquired":true,"shares":97094,"price":2.35,"value":228170.9,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"These Shares were purchased in multiple transactions at prices ranging from $2.22 to $2.46. The price reported reflects the weighted average purchase price. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Shares purchased at each separate price within the ranges set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The Shares are held of record by OrbiMed Private Investments V - KA, LP (\"OPI V-KA\"). OrbiMed Capital GP V LLC (\"GP V\") is the general partner of OPI V-KA, and OrbiMed Advisors LLC (\"OrbiMed Advisors\"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the managing member of GP V. By virtue of such relationships, GP V and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by OPI V-KA. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the Shares held by OPI V-KA."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"This report on Form 4 is jointly filed by GP V, OrbiMed Advisors, and Genesis GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors and GP V have designated Carl L. Gordon (\"Gordon\"), a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Persons, or Gordon, is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":14787272,"source":{"system":"sec-edgar","filing":"0000947871-22-000567","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787122000567/ownership.xml","form_type":"4"}},{"id":2272463,"issuer":{"id":5614,"kind":"organization","name":"Compass Therapeutics, Inc.","symbol":"CMPX"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53130,"kind":"organization","name":"OrbiMed Capital GP V LLC","position":2,"cik":"0001615374","reported_name":"OrbiMed Capital GP V LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":3,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-05-13T21:45:38.000Z","date":"2022-05-11","kind":"purchase","acquired":true,"shares":64700,"price":1.79,"value":115813.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"These shares of the Issuer's common stock (\"Shares\") were purchased in multiple transactions at prices ranging from $1.79 to $1.80. The price reported reflects the weighted average purchase price. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Shares purchased at each separate price within the ranges set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The Shares are held of record by OrbiMed Private Investments V - KA, LP (\"OPI V-KA\"). OrbiMed Capital GP V LLC (\"GP V\") is the general partner of OPI V-KA, and OrbiMed Advisors LLC (\"OrbiMed Advisors\"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the managing member of GP V. By virtue of such relationships, GP V and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by OPI V-KA. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the Shares held by OPI V-KA."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"This report on Form 4 is jointly filed by GP V, OrbiMed Advisors, and Genesis GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors and GP V have designated Carl L. Gordon (\"Gordon\"), a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Persons, or Gordon, is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":14690178,"source":{"system":"sec-edgar","filing":"0000947871-22-000567","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787122000567/ownership.xml","form_type":"4"}},{"id":2276523,"issuer":{"id":5614,"kind":"organization","name":"Compass Therapeutics, Inc.","symbol":"CMPX"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53130,"kind":"organization","name":"OrbiMed Capital GP V LLC","position":2,"cik":"0001615374","reported_name":"OrbiMed Capital GP V LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":3,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-05-10T22:21:45.000Z","date":"2022-05-10","kind":"purchase","acquired":true,"shares":24447,"price":1.6,"value":39115.2,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"These Shares were purchased in a block at a price of $1.60."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The Shares are held of record by OrbiMed Private Investments V - KA, LP (\"OPI V-KA\"). OrbiMed Capital GP V LLC (\"GP V\") is the general partner of OPI V-KA, and OrbiMed Advisors LLC (\"OrbiMed Advisors\"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the managing member of GP V. By virtue of such relationships, GP V and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by OPI V-KA. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the Shares held by OPI V-KA."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"This report on Form 4 is jointly filed by GP V, OrbiMed Advisors, and Genesis GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors and GP V have designated Carl L. Gordon (\"Gordon\"), a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Persons, or Gordon, is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":14625478,"source":{"system":"sec-edgar","filing":"0000947871-22-000540","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787122000540/ownership.xml","form_type":"4"}},{"id":2276522,"issuer":{"id":5614,"kind":"organization","name":"Compass Therapeutics, Inc.","symbol":"CMPX"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53130,"kind":"organization","name":"OrbiMed Capital GP V LLC","position":2,"cik":"0001615374","reported_name":"OrbiMed Capital GP V LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":3,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-05-10T22:21:45.000Z","date":"2022-05-09","kind":"purchase","acquired":true,"shares":90712,"price":1.56,"value":141510.72,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"These Shares were purchased in a block at a price of $1.56."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The Shares are held of record by OrbiMed Private Investments V - KA, LP (\"OPI V-KA\"). OrbiMed Capital GP V LLC (\"GP V\") is the general partner of OPI V-KA, and OrbiMed Advisors LLC (\"OrbiMed Advisors\"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the managing member of GP V. By virtue of such relationships, GP V and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by OPI V-KA. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the Shares held by OPI V-KA."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"This report on Form 4 is jointly filed by GP V, OrbiMed Advisors, and Genesis GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors and GP V have designated Carl L. Gordon (\"Gordon\"), a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Persons, or Gordon, is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":14601031,"source":{"system":"sec-edgar","filing":"0000947871-22-000540","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787122000540/ownership.xml","form_type":"4"}},{"id":2276521,"issuer":{"id":5614,"kind":"organization","name":"Compass Therapeutics, Inc.","symbol":"CMPX"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53130,"kind":"organization","name":"OrbiMed Capital GP V LLC","position":2,"cik":"0001615374","reported_name":"OrbiMed Capital GP V LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":3,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-05-10T22:21:45.000Z","date":"2022-05-06","kind":"purchase","acquired":true,"shares":10200,"price":1.63,"value":16626.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"These shares of the Issuer's common stock (\"Shares\") were purchased in a block at a price of $1.63."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The Shares are held of record by OrbiMed Private Investments V - KA, LP (\"OPI V-KA\"). OrbiMed Capital GP V LLC (\"GP V\") is the general partner of OPI V-KA, and OrbiMed Advisors LLC (\"OrbiMed Advisors\"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the managing member of GP V. By virtue of such relationships, GP V and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by OPI V-KA. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the Shares held by OPI V-KA."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"This report on Form 4 is jointly filed by GP V, OrbiMed Advisors, and Genesis GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors and GP V have designated Carl L. Gordon (\"Gordon\"), a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Persons, or Gordon, is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":14510319,"source":{"system":"sec-edgar","filing":"0000947871-22-000540","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787122000540/ownership.xml","form_type":"4"}},{"id":2313353,"issuer":{"id":7062,"kind":"organization","name":"PMV Pharmaceuticals, Inc.","symbol":"PMVP"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53130,"kind":"organization","name":"OrbiMed Capital GP V LLC","position":2,"cik":"0001615374","reported_name":"OrbiMed Capital GP V LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":3,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51518,"kind":"person","name":"ORBIMED CAPITAL LLC","position":4,"cik":"0001157524","reported_name":"ORBIMED CAPITAL LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-03-31T21:30:50.000Z","date":"2022-03-31","kind":"sale","acquired":false,"shares":34500,"price":21.17,"value":730365.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"These shares of the Issuer's common stock (\"Shares\") were sold in a block at a price of $21.17."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares are held of record by OrbiMed Partners Master Fund Limited (\"OPM\"). OrbiMed Capital LLC (\"OrbiMed Capital\") is the investment advisor to OPM. OrbiMed Capital exercises voting and investment power through a management committee comprised of the Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPM."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"This report on Form 4 is jointly filed by OrbiMed Advisors LLC, GP V, Genesis GP, and OrbiMed Capital. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1943, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000947871-22-000429","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787122000429/ownership.xml","form_type":"4"}},{"id":2313352,"issuer":{"id":7062,"kind":"organization","name":"PMV Pharmaceuticals, Inc.","symbol":"PMVP"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53130,"kind":"organization","name":"OrbiMed Capital GP V LLC","position":2,"cik":"0001615374","reported_name":"OrbiMed Capital GP V LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":3,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51518,"kind":"person","name":"ORBIMED CAPITAL LLC","position":4,"cik":"0001157524","reported_name":"ORBIMED CAPITAL LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-03-31T21:30:50.000Z","date":"2022-03-30","kind":"sale","acquired":false,"shares":75000,"price":22.39,"value":1679250.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"These shares of the Issuer's common stock (\"Shares\") were sold in a block at a price of $22.39."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares are held of record by OrbiMed Partners Master Fund Limited (\"OPM\"). OrbiMed Capital LLC (\"OrbiMed Capital\") is the investment advisor to OPM. OrbiMed Capital exercises voting and investment power through a management committee comprised of the Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPM."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"This report on Form 4 is jointly filed by OrbiMed Advisors LLC, GP V, Genesis GP, and OrbiMed Capital. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1943, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":34500,"source":{"system":"sec-edgar","filing":"0000947871-22-000429","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787122000429/ownership.xml","form_type":"4"}},{"id":2313351,"issuer":{"id":7062,"kind":"organization","name":"PMV Pharmaceuticals, Inc.","symbol":"PMVP"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53130,"kind":"organization","name":"OrbiMed Capital GP V LLC","position":2,"cik":"0001615374","reported_name":"OrbiMed Capital GP V LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":3,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51518,"kind":"person","name":"ORBIMED CAPITAL LLC","position":4,"cik":"0001157524","reported_name":"ORBIMED CAPITAL LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-03-31T21:30:50.000Z","date":"2022-03-29","kind":"sale","acquired":false,"shares":365000,"price":21.52,"value":7854800.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"These shares of the Issuer's common stock (\"Shares\") were sold in a block at a price of $21.52."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares are held of record by OrbiMed Partners Master Fund Limited (\"OPM\"). OrbiMed Capital LLC (\"OrbiMed Capital\") is the investment advisor to OPM. OrbiMed Capital exercises voting and investment power through a management committee comprised of the Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPM."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"This report on Form 4 is jointly filed by OrbiMed Advisors LLC, GP V, Genesis GP, and OrbiMed Capital. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1943, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":109500,"source":{"system":"sec-edgar","filing":"0000947871-22-000429","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787122000429/ownership.xml","form_type":"4"}},{"id":2474025,"issuer":{"id":6860,"kind":"organization","name":"Adicet Bio, Inc."},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53130,"kind":"organization","name":"OrbiMed Capital GP V LLC","position":2,"cik":"0001615374","reported_name":"OrbiMed Capital GP V LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51517,"kind":"person","name":"OrbiMed Capital GP VI LLC","position":3,"cik":"0001682115","reported_name":"OrbiMed Capital GP VI LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":4,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53131,"kind":"organization","name":"OrbiMed Advisors Israel II Ltd","position":5,"cik":"0001682093","reported_name":"OrbiMed Advisors Israel II Ltd","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53132,"kind":"organization","name":"OrbiMed Israel GP II, L.P.","position":6,"cik":"0001682090","reported_name":"OrbiMed Israel GP II, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53133,"kind":"organization","name":"OrbiMed Israel GP Ltd.","position":7,"cik":"0001569590","reported_name":"OrbiMed Israel GP Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53134,"kind":"organization","name":"OrbiMed Israel BioFund GP Limited Partnership","position":8,"cik":"0001569821","reported_name":"OrbiMed Israel BioFund GP Limited Partnership","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-12-14T23:41:26.000Z","date":"2021-12-10","kind":"grant","acquired":true,"shares":214285,"price":14,"value":2999990.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"These shares of the Issuer's common stock were purchased in the Issuer's underwritten public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These shares of the Issuer's common stock are held of record by OrbiMed Genesis Master Fund, L.P. (\"Genesis\"). OrbiMed Genesis GP LLC (\"Genesis GP\") is the general partner of Genesis, and OrbiMed Advisors is the managing member of Genesis. By virtue of such relationships, Genesis GP and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by Genesis noted above and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Exchange Act. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the Shares held by Genesis."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"This report is being jointly filed by OrbiMed Advisors, GP V, GP VI, Genesis, OrbiMed Israel GP II, OrbiMed Israel II, OrbiMed BioFund, and OrbiMed Israel GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors, GP V, GP VI, OrbiMed Israel GP II, OrbiMed Israel II, OrbiMed BioFund, and OrbiMed Israel GP have designated Carl L. Gordon (\"Gordon\") to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Persons or Gordon is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":242285,"source":{"system":"sec-edgar","filing":"0000947871-21-001280","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787121001280/ownership.xml","form_type":"4"}},{"id":2508349,"issuer":{"id":122050,"kind":"organization","name":"Tricida, Inc.","symbol":"TCDA"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53130,"kind":"organization","name":"OrbiMed Capital GP V LLC","position":2,"cik":"0001615374","reported_name":"OrbiMed Capital GP V LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Comm on Warrants to Purchase Common Stock","published_at":"2021-11-17T21:09:57.000Z","date":"2021-11-15","kind":"grant","acquired":true,"shares":666667,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"security","element":"securityTitle","label":"F5","text":"The common warrants may be exercised for shares of common stock at any time on or after the date that is six months after the date of their issuance."},{"field":"shares","element":"transactionShares","label":"F1","text":"These shares of common stock and these common warrants were acquired directly from Tricida, Inc. (the \"Issuer\") in a registered direct offering. For each share purchased in the registered direct offering, at a price of $6.00 per share of common stock, the purchaser received one warrant."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"These shares of common stock and these common warrants were acquired directly from Tricida, Inc. (the \"Issuer\") in a registered direct offering. For each share purchased in the registered direct offering, at a price of $6.00 per share of common stock, the purchaser received one warrant."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The common warrants may be exercised for shares of common stock at any time on or after the date that is six months after the date of their issuance."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"The expiration date is the earliest of: (a) the third anniversary of the date of their issuance, (b) immediately prior to the closing of a fundamental transaction or (c) the occurrence of certain other events. A \"fundamental transaction\" includes a consolidation or merger, the sale, transfer or other disposition of all or substantially all of the Issuer's properties or assets, the acquisition of more than 50% of the Issuer's outstanding common stock, any reorganization, recapitalization or reclassification of the Issuer's common stock or any person or group becoming the beneficial owner of 50% of the voting power represented by the Issuer's outstanding common stock."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by OrbiMed Private Investments V, LP (\"OPI V\"). OrbiMed Capital GP V LLC (\"GP V\") is the general partner of OPI V, and OrbiMed Advisors LLC (\"Advisors\"), a registered adviser under the Investment Advisors Act of 1940, as amended, is the managing member of GP V. By virtue of such relationships, GP V and Advisors may be deemed to have voting and investment power with respect to the shares held by OPI V. Advisors exercises investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the Shares held by OPI V."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"This report on Form 4 is jointly filed by GP V and Advisors. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated a representative, David P. Bonita (\"Bonita\"), a member of Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Persons, or Bonita, is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act, or for any other purposes."}],"balance_after":666667,"derivative":{"exercise_price":11,"underlying":"Common Stock","underlying_shares":666667},"source":{"system":"sec-edgar","filing":"0000947871-21-001212","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787121001212/ownership.xml","form_type":"4"}},{"id":2508348,"issuer":{"id":122050,"kind":"organization","name":"Tricida, Inc.","symbol":"TCDA"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53130,"kind":"organization","name":"OrbiMed Capital GP V LLC","position":2,"cik":"0001615374","reported_name":"OrbiMed Capital GP V LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-11-17T21:09:57.000Z","date":"2021-11-15","kind":"grant","acquired":true,"shares":666667,"price":6,"value":4000002.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares of common stock and these common warrants were acquired directly from Tricida, Inc. (the \"Issuer\") in a registered direct offering. For each share purchased in the registered direct offering, at a price of $6.00 per share of common stock, the purchaser received one warrant."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"These securities are held of record by OrbiMed Private Investments V, LP (\"OPI V\"). OrbiMed Capital GP V LLC (\"GP V\") is the general partner of OPI V, and OrbiMed Advisors LLC (\"Advisors\"), a registered adviser under the Investment Advisors Act of 1940, as amended, is the managing member of GP V. By virtue of such relationships, GP V and Advisors may be deemed to have voting and investment power with respect to the shares held by OPI V. Advisors exercises investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the Shares held by OPI V."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by OrbiMed Private Investments V, LP (\"OPI V\"). OrbiMed Capital GP V LLC (\"GP V\") is the general partner of OPI V, and OrbiMed Advisors LLC (\"Advisors\"), a registered adviser under the Investment Advisors Act of 1940, as amended, is the managing member of GP V. By virtue of such relationships, GP V and Advisors may be deemed to have voting and investment power with respect to the shares held by OPI V. Advisors exercises investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the Shares held by OPI V."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"This report on Form 4 is jointly filed by GP V and Advisors. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated a representative, David P. Bonita (\"Bonita\"), a member of Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Persons, or Bonita, is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act, or for any other purposes."}],"balance_after":10280947,"source":{"system":"sec-edgar","filing":"0000947871-21-001212","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787121001212/ownership.xml","form_type":"4"}},{"id":2521784,"issuer":{"id":5614,"kind":"organization","name":"Compass Therapeutics, Inc.","symbol":"CMPX"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53130,"kind":"organization","name":"OrbiMed Capital GP V LLC","position":2,"cik":"0001615374","reported_name":"OrbiMed Capital GP V LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":3,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-11-09T02:06:06.000Z","date":"2021-11-04","kind":"purchase","acquired":true,"shares":3571428,"price":3.5,"value":12499998.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"These shares of the Issuer's common stock were purchased in the Issuer's underwritten public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These shares of the Issuer's common stock are held of record by OrbiMed Genesis Master Fund, L.P. (\"Genesis Master Fund\"). OrbiMed Genesis GP LLC (\"Genesis GP\") is the general partner of Genesis Master Fund and OrbiMed Advisors is the managing member of Genesis GP. OrbiMed Advisors and Genesis GP exercise investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the securities held by Genesis Master Fund."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"This report on Form 4 is jointly filed by GP V, OrbiMed Advisors, and Genesis GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors and GP V have designated Carl L. Gordon (\"Gordon\"), a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Persons, or Gordon, is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":3571428,"source":{"system":"sec-edgar","filing":"0000947871-21-001150","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787121001150/ownership.xml","form_type":"4"}},{"id":2521783,"issuer":{"id":5614,"kind":"organization","name":"Compass Therapeutics, Inc.","symbol":"CMPX"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53130,"kind":"organization","name":"OrbiMed Capital GP V LLC","position":2,"cik":"0001615374","reported_name":"OrbiMed Capital GP V LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":3,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-11-09T02:06:06.000Z","date":"2021-11-04","kind":"purchase","acquired":true,"shares":1785715,"price":3.5,"value":6250002.5,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"These shares of the Issuer's common stock were purchased in the Issuer's underwritten public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares of the Issuer's common stock are held of record by OrbiMed Private Investments V - KA, LP (\"OPI V-KA\"). OrbiMed Capital GP V LLC (\"GP V\") is the general partner of OPI V-KA, and OrbiMed Advisors LLC (\"OrbiMed Advisors\"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the managing member of GP V. OrbiMed Advisors and GP V exercise investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the Shares held by OPI V-KA."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"This report on Form 4 is jointly filed by GP V, OrbiMed Advisors, and Genesis GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors and GP V have designated Carl L. Gordon (\"Gordon\"), a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Persons, or Gordon, is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":14500119,"source":{"system":"sec-edgar","filing":"0000947871-21-001150","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787121001150/ownership.xml","form_type":"4"}},{"id":2562329,"issuer":{"id":4839,"kind":"organization","name":"Corvus Pharmaceuticals, Inc."},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53130,"kind":"organization","name":"OrbiMed Capital GP V LLC","position":2,"cik":"0001615374","reported_name":"OrbiMed Capital GP V LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, $0.0001 par value","published_at":"2021-09-22T21:27:24.000Z","date":"2021-09-20","kind":"sale","acquired":false,"shares":1109644,"price":6.09,"value":6757731.96,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price in column 4 is a weighted average price. These shares of the Issuer's common stock were sold in multiple transactions at prices ranging from $6.01 to $6.09. The Reporting Persons undertake to provide Corvus Pharmaceuticals, Inc., any security holder of Corvus Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares of the Issuer's common stock are held of record by OrbiMed Private Investments V, LP (\"OPI V\"). OrbiMed Capital GP V LLC (\"GP V\") is the general partner of OPI V, and OrbiMed Advisors LLC (\"OrbiMed Advisors\"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the managing member of GP V. OrbiMed Advisors and GP V exercise investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the Shares held by OPI V."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"This report is being jointly filed by OrbiMed Advisors and GP V. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated Peter Thompson (\"Thompson\"), an employee of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Persons or Thompson is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":6943654,"source":{"system":"sec-edgar","filing":"0000947871-21-001017","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787121001017/ownership.xml","form_type":"4"}},{"id":2846870,"issuer":{"id":4839,"kind":"organization","name":"Corvus Pharmaceuticals, Inc."},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53130,"kind":"organization","name":"OrbiMed Capital GP V LLC","position":2,"cik":"0001615374","reported_name":"OrbiMed Capital GP V LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, $0.0001 par value","published_at":"2021-02-19T21:52:11.000Z","date":"2021-02-17","kind":"purchase","acquired":true,"shares":1285714,"price":3.5,"value":4499999.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares of the Issuer's common stock (\"Shares\") were purchased in a registered public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares of the Issuer's common stock are held of record by OrbiMed Private Investments V, LP (\"OPI V\"). OrbiMed Capital GP V LLC (\"GP V\") is the general partner of OPI V, and OrbiMed Advisors LLC (\"OrbiMed Advisors\"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the managing member of GP V. By virtue of such relationships, GP V and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by OPI V noted above and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Exchange Act. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the Shares held by OPI V."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"This report is being jointly filed by OrbiMed Advisors and GP V. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated Peter Thompson (\"Thompson\"), an employee of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Persons or Thompson is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":8053298,"source":{"system":"sec-edgar","filing":"0000947871-21-000249","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787121000249/ownership.xml","form_type":"4"}},{"id":2851473,"issuer":{"id":6860,"kind":"organization","name":"Adicet Bio, Inc."},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53130,"kind":"organization","name":"OrbiMed Capital GP V LLC","position":2,"cik":"0001615374","reported_name":"OrbiMed Capital GP V LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51517,"kind":"person","name":"OrbiMed Capital GP VI LLC","position":3,"cik":"0001682115","reported_name":"OrbiMed Capital GP VI LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53131,"kind":"organization","name":"OrbiMed Advisors Israel II Ltd","position":4,"cik":"0001682093","reported_name":"OrbiMed Advisors Israel II Ltd","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53132,"kind":"organization","name":"OrbiMed Israel GP II, L.P.","position":5,"cik":"0001682090","reported_name":"OrbiMed Israel GP II, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53133,"kind":"organization","name":"OrbiMed Israel GP Ltd.","position":6,"cik":"0001569590","reported_name":"OrbiMed Israel GP Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53134,"kind":"organization","name":"OrbiMed Israel BioFund GP Limited Partnership","position":7,"cik":"0001569821","reported_name":"OrbiMed Israel BioFund GP Limited Partnership","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-02-19T02:38:27.000Z","date":"2021-02-12","kind":"grant","acquired":true,"shares":104050,"price":13,"value":1352650.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"These shares of the Issuer's common stock were purchased in a private placement exempt from the registration requirements of the Securities Act of 1933, as amended."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"These shares of the Issuer's common stock are held of record by OrbiMed Israel Partners II, L.P. (\"OIP II\"). OrbiMed Israel GP II, L.P. (\"OrbiMed Israel GP II\") is the general partner of OIP II, and OrbiMed Advisors Israel II Limited (\"OrbiMed Israel II\") is the general partner of OrbiMed Israel GP II. By virtue of such relationships, OrbiMed Israel GP II and OrbiMed Israel II may be deemed to have voting and investment power with respect to the shares held directly by OIP II noted above and, as a result, may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Exchange Act. OrbiMed Israel II exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Jonathan T. Silverstein, Nissim Darvish, Anat Naschitz, and Chimovits, each of whom disclaims beneficial ownership of the shares held by OIP II."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"This report is being jointly filed by OrbiMed Advisors, GP V, GP VI, OrbiMed Israel GP II, OrbiMed Israel II, OrbiMed BioFund. and OrbiMed Israel GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Persons are a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose. The Reporting Persons have designated Carl L. Gordon (\"Gordon\") and Erez Chimovits (\"Chimovits\") to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Persons, Gordon, or Chimovits is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":396657,"source":{"system":"sec-edgar","filing":"0000947871-21-000240","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787121000240/ownership.xml","form_type":"4"}},{"id":2851472,"issuer":{"id":6860,"kind":"organization","name":"Adicet Bio, Inc."},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53130,"kind":"organization","name":"OrbiMed Capital GP V LLC","position":2,"cik":"0001615374","reported_name":"OrbiMed Capital GP V LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51517,"kind":"person","name":"OrbiMed Capital GP VI LLC","position":3,"cik":"0001682115","reported_name":"OrbiMed Capital GP VI LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53131,"kind":"organization","name":"OrbiMed Advisors Israel II Ltd","position":4,"cik":"0001682093","reported_name":"OrbiMed Advisors Israel II Ltd","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53132,"kind":"organization","name":"OrbiMed Israel GP II, L.P.","position":5,"cik":"0001682090","reported_name":"OrbiMed Israel GP II, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53133,"kind":"organization","name":"OrbiMed Israel GP Ltd.","position":6,"cik":"0001569590","reported_name":"OrbiMed Israel GP Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53134,"kind":"organization","name":"OrbiMed Israel BioFund GP Limited Partnership","position":7,"cik":"0001569821","reported_name":"OrbiMed Israel BioFund GP Limited Partnership","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-02-19T02:38:27.000Z","date":"2021-02-12","kind":"grant","acquired":true,"shares":420299,"price":13,"value":5463887.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"These shares of the Issuer's common stock were purchased in a private placement exempt from the registration requirements of the Securities Act of 1933, as amended."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These shares of the Issuer's common stock are held of record by OrbiMed Private Investments V, LP (\"OPI V\"). OrbiMed Capital GP V LLC (\"GP V\") is the general partner of OPI V, and OrbiMed Advisors is the managing member of GP V. By virtue of such relationships, GP V and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by OPI V noted above and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Exchange Act. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the Shares held by OPI V."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"This report is being jointly filed by OrbiMed Advisors, GP V, GP VI, OrbiMed Israel GP II, OrbiMed Israel II, OrbiMed BioFund. and OrbiMed Israel GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Persons are a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose. The Reporting Persons have designated Carl L. Gordon (\"Gordon\") and Erez Chimovits (\"Chimovits\") to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Persons, Gordon, or Chimovits is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":5243259,"source":{"system":"sec-edgar","filing":"0000947871-21-000240","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787121000240/ownership.xml","form_type":"4"}},{"id":2950416,"issuer":{"id":6074,"kind":"organization","name":"Whitehawk Therapeutics, Inc.","symbol":"WHWK"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53130,"kind":"organization","name":"OrbiMed Capital GP V LLC","position":2,"cik":"0001615374","reported_name":"OrbiMed Capital GP V LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-12-10T22:04:43.000Z","date":"2020-12-08","kind":"other","acquired":false,"shares":21400,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This option was granted to Khuong on June 18, 2019 and vested on the first anniversary of the grant date. Pursuant to an agreement with OrbiMed Advisors and GP V, Khuong is obligated to transfer these securities, or the economic benefit thereof, to OrbiMed Advisors and GP V, which will in turn ensure that such securities or economic benefits are provided to OPI V."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Each of the GP V, OrbiMed Advisors, and Khuong disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) of the Exchange Act, except to the extent of its or his pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity or person, including the Reporting Persons, is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"This option was granted to Khuong on June 18, 2019 and vested on the first anniversary of the grant date. Pursuant to an agreement with OrbiMed Advisors and GP V, Khuong is obligated to transfer these securities, or the economic benefit thereof, to OrbiMed Advisors and GP V, which will in turn ensure that such securities or economic benefits are provided to OPI V."}],"balance_after":0,"derivative":{"exercise_price":0.96,"expiration_date":"2029-06-28","underlying":"Common Stock","underlying_shares":21400},"source":{"system":"sec-edgar","filing":"0000947871-20-000944","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787120000944/ownership.xml","form_type":"4"}},{"id":2950415,"issuer":{"id":6074,"kind":"organization","name":"Whitehawk Therapeutics, Inc.","symbol":"WHWK"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53130,"kind":"organization","name":"OrbiMed Capital GP V LLC","position":2,"cik":"0001615374","reported_name":"OrbiMed Capital GP V LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-12-10T22:04:43.000Z","date":"2020-12-08","kind":"sale","acquired":false,"shares":21400,"price":1.96,"value":41944.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.94 to $2.00. The Reporting Persons"},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"This shares are held by Chau Khuong (\"Khuong\"). OrbiMed Advisors LLC (\"OrbiMed Advisors\"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the managing member of OrbiMed Capital GP V LLC (\"GP V\"), which is the general partner of OrbiMed Private Investments V, LP (\"OPI V\"). Pursuant to an agreement with OrbiMed Advisors and GP V, Khuong is obligated to transfer these securities, or the economic benefit thereof, to OrbiMed Advisors and GP V, which will in turn ensure that such securities or economic benefits are provided to OPI V."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Each of the GP V, OrbiMed Advisors, and Khuong disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) of the Exchange Act, except to the extent of its or his pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity or person, including the Reporting Persons, is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000947871-20-000944","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787120000944/ownership.xml","form_type":"4"}},{"id":2950414,"issuer":{"id":6074,"kind":"organization","name":"Whitehawk Therapeutics, Inc.","symbol":"WHWK"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53130,"kind":"organization","name":"OrbiMed Capital GP V LLC","position":2,"cik":"0001615374","reported_name":"OrbiMed Capital GP V LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-12-10T22:04:43.000Z","date":"2020-12-08","kind":"other","acquired":true,"shares":21400,"price":0.96,"value":20544.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"This shares are held by Chau Khuong (\"Khuong\"). OrbiMed Advisors LLC (\"OrbiMed Advisors\"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the managing member of OrbiMed Capital GP V LLC (\"GP V\"), which is the general partner of OrbiMed Private Investments V, LP (\"OPI V\"). Pursuant to an agreement with OrbiMed Advisors and GP V, Khuong is obligated to transfer these securities, or the economic benefit thereof, to OrbiMed Advisors and GP V, which will in turn ensure that such securities or economic benefits are provided to OPI V."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Each of the GP V, OrbiMed Advisors, and Khuong disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) of the Exchange Act, except to the extent of its or his pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity or person, including the Reporting Persons, is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":21400,"source":{"system":"sec-edgar","filing":"0000947871-20-000944","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787120000944/ownership.xml","form_type":"4"}},{"id":3020983,"issuer":{"id":7062,"kind":"organization","name":"PMV Pharmaceuticals, Inc.","symbol":"PMVP"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53130,"kind":"organization","name":"OrbiMed Capital GP V LLC","position":2,"cik":"0001615374","reported_name":"OrbiMed Capital GP V LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":3,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51518,"kind":"person","name":"ORBIMED CAPITAL LLC","position":4,"cik":"0001157524","reported_name":"ORBIMED CAPITAL LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series D Preferred Stock","published_at":"2020-09-29T20:39:56.000Z","date":"2020-09-29","kind":"exercise","acquired":false,"shares":114039,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The shares of each of the Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and have no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares of each of the Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The shares of each of the Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and have no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"This report on Form 4 is jointly filed by OrbiMed Advisors, GP V, OrbiMed Genesis GP LLC (\"Genesis GP\") and OrbiMed Capital LLC (\"OrbiMed Capital\"). Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose. The Reporting Persons have designated a representative, Peter Thompson, an employee of OrbiMed Advisors, to serve on the Issuer's board of directors."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares are held of record by OrbiMed Genesis Master Fund, L.P. (\"Genesis Master Fund\"). Genesis GP is the general partner of Genesis Master Fund and OrbiMed Advisors is the managing member of Genesis GP. By virtue of such relationships, Genesis GP and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by Genesis Master Fund and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the shares held by Genesis Master Fund."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":114039},"source":{"system":"sec-edgar","filing":"0001209191-20-052339","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000120919120052339/doc4.xml","form_type":"4"}},{"id":3020982,"issuer":{"id":7062,"kind":"organization","name":"PMV Pharmaceuticals, Inc.","symbol":"PMVP"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53130,"kind":"organization","name":"OrbiMed Capital GP V LLC","position":2,"cik":"0001615374","reported_name":"OrbiMed Capital GP V LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":3,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51518,"kind":"person","name":"ORBIMED CAPITAL LLC","position":4,"cik":"0001157524","reported_name":"ORBIMED CAPITAL LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series D Preferred Stock","published_at":"2020-09-29T20:39:56.000Z","date":"2020-09-29","kind":"exercise","acquired":false,"shares":380133,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The shares of each of the Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and have no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares of each of the Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The shares of each of the Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and have no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The shares are held of record by OrbiMed Private Investments V, LP (\"OPI V\"). OrbiMed Capital GP V LLC (\"GP V\") is the general partner of OPI V, and OrbiMed Advisors LLC (\"OrbiMed Advisors\"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the managing member of GP V. By virtue of such relationships, GP V and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by OPI V noted above and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"). OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the shares held by OPI V."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"This report on Form 4 is jointly filed by OrbiMed Advisors, GP V, OrbiMed Genesis GP LLC (\"Genesis GP\") and OrbiMed Capital LLC (\"OrbiMed Capital\"). Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose. The Reporting Persons have designated a representative, Peter Thompson, an employee of OrbiMed Advisors, to serve on the Issuer's board of directors."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":380133},"source":{"system":"sec-edgar","filing":"0001209191-20-052339","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000120919120052339/doc4.xml","form_type":"4"}},{"id":3020981,"issuer":{"id":7062,"kind":"organization","name":"PMV Pharmaceuticals, Inc.","symbol":"PMVP"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53130,"kind":"organization","name":"OrbiMed Capital GP V LLC","position":2,"cik":"0001615374","reported_name":"OrbiMed Capital GP V LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":3,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51518,"kind":"person","name":"ORBIMED CAPITAL LLC","position":4,"cik":"0001157524","reported_name":"ORBIMED CAPITAL LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Preferred Stock","published_at":"2020-09-29T20:39:56.000Z","date":"2020-09-29","kind":"exercise","acquired":false,"shares":518191,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The shares of each of the Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and have no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares of each of the Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The shares of each of the Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and have no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The shares are held of record by OrbiMed Private Investments V, LP (\"OPI V\"). OrbiMed Capital GP V LLC (\"GP V\") is the general partner of OPI V, and OrbiMed Advisors LLC (\"OrbiMed Advisors\"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the managing member of GP V. By virtue of such relationships, GP V and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by OPI V noted above and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"). OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the shares held by OPI V."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"This report on Form 4 is jointly filed by OrbiMed Advisors, GP V, OrbiMed Genesis GP LLC (\"Genesis GP\") and OrbiMed Capital LLC (\"OrbiMed Capital\"). Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose. The Reporting Persons have designated a representative, Peter Thompson, an employee of OrbiMed Advisors, to serve on the Issuer's board of directors."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":518191},"source":{"system":"sec-edgar","filing":"0001209191-20-052339","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000120919120052339/doc4.xml","form_type":"4"}},{"id":3020980,"issuer":{"id":7062,"kind":"organization","name":"PMV Pharmaceuticals, Inc.","symbol":"PMVP"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53130,"kind":"organization","name":"OrbiMed Capital GP V LLC","position":2,"cik":"0001615374","reported_name":"OrbiMed Capital GP V LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":3,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51518,"kind":"person","name":"ORBIMED CAPITAL LLC","position":4,"cik":"0001157524","reported_name":"ORBIMED CAPITAL LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2020-09-29T20:39:56.000Z","date":"2020-09-29","kind":"exercise","acquired":false,"shares":1076891,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The shares of each of the Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and have no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares of each of the Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The shares of each of the Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and have no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The shares are held of record by OrbiMed Private Investments V, LP (\"OPI V\"). OrbiMed Capital GP V LLC (\"GP V\") is the general partner of OPI V, and OrbiMed Advisors LLC (\"OrbiMed Advisors\"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the managing member of GP V. By virtue of such relationships, GP V and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by OPI V noted above and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"). OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the shares held by OPI V."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"This report on Form 4 is jointly filed by OrbiMed Advisors, GP V, OrbiMed Genesis GP LLC (\"Genesis GP\") and OrbiMed Capital LLC (\"OrbiMed Capital\"). Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose. The Reporting Persons have designated a representative, Peter Thompson, an employee of OrbiMed Advisors, to serve on the Issuer's board of directors."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1076891},"source":{"system":"sec-edgar","filing":"0001209191-20-052339","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000120919120052339/doc4.xml","form_type":"4"}},{"id":3020979,"issuer":{"id":7062,"kind":"organization","name":"PMV Pharmaceuticals, Inc.","symbol":"PMVP"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53130,"kind":"organization","name":"OrbiMed Capital GP V LLC","position":2,"cik":"0001615374","reported_name":"OrbiMed Capital GP V LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":3,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51518,"kind":"person","name":"ORBIMED CAPITAL LLC","position":4,"cik":"0001157524","reported_name":"ORBIMED CAPITAL LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Preferred Stock","published_at":"2020-09-29T20:39:56.000Z","date":"2020-09-29","kind":"exercise","acquired":false,"shares":4025076,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The shares of each of the Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and have no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares of each of the Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The shares of each of the Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and have no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The shares are held of record by OrbiMed Private Investments V, LP (\"OPI V\"). OrbiMed Capital GP V LLC (\"GP V\") is the general partner of OPI V, and OrbiMed Advisors LLC (\"OrbiMed Advisors\"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the managing member of GP V. By virtue of such relationships, GP V and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by OPI V noted above and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"). OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the shares held by OPI V."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"This report on Form 4 is jointly filed by OrbiMed Advisors, GP V, OrbiMed Genesis GP LLC (\"Genesis GP\") and OrbiMed Capital LLC (\"OrbiMed Capital\"). Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose. The Reporting Persons have designated a representative, Peter Thompson, an employee of OrbiMed Advisors, to serve on the Issuer's board of directors."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":4025076},"source":{"system":"sec-edgar","filing":"0001209191-20-052339","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000120919120052339/doc4.xml","form_type":"4"}},{"id":3020978,"issuer":{"id":7062,"kind":"organization","name":"PMV Pharmaceuticals, Inc.","symbol":"PMVP"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53130,"kind":"organization","name":"OrbiMed Capital GP V LLC","position":2,"cik":"0001615374","reported_name":"OrbiMed Capital GP V LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":3,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51518,"kind":"person","name":"ORBIMED CAPITAL LLC","position":4,"cik":"0001157524","reported_name":"ORBIMED CAPITAL LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-09-29T20:39:56.000Z","date":"2020-09-25","kind":"purchase","acquired":true,"shares":475000,"price":18,"value":8550000.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"This report on Form 4 is jointly filed by OrbiMed Advisors, GP V, OrbiMed Genesis GP LLC (\"Genesis GP\") and OrbiMed Capital LLC (\"OrbiMed Capital\"). Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose. The Reporting Persons have designated a representative, Peter Thompson, an employee of OrbiMed Advisors, to serve on the Issuer's board of directors."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The shares are held of record by OrbiMed Partners Master Fund Limited (\"OPM\"). OrbiMed Capital is the investment advisor to OPM. OrbiMed Capital is a relying advisor of OrbiMed Advisors. OrbiMed Advisors and OrbiMed Capital exercise voting and investment power through a management committee comprised of the Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the shares held by OPM."}],"balance_after":475000,"source":{"system":"sec-edgar","filing":"0001209191-20-052339","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000120919120052339/doc4.xml","form_type":"4"}},{"id":3020977,"issuer":{"id":7062,"kind":"organization","name":"PMV Pharmaceuticals, Inc.","symbol":"PMVP"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53130,"kind":"organization","name":"OrbiMed Capital GP V LLC","position":2,"cik":"0001615374","reported_name":"OrbiMed Capital GP V LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":3,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51518,"kind":"person","name":"ORBIMED CAPITAL LLC","position":4,"cik":"0001157524","reported_name":"ORBIMED CAPITAL LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-09-29T20:39:56.000Z","date":"2020-09-29","kind":"exercise","acquired":true,"shares":114039,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The shares of each of the Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and have no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"This report on Form 4 is jointly filed by OrbiMed Advisors, GP V, OrbiMed Genesis GP LLC (\"Genesis GP\") and OrbiMed Capital LLC (\"OrbiMed Capital\"). Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose. The Reporting Persons have designated a representative, Peter Thompson, an employee of OrbiMed Advisors, to serve on the Issuer's board of directors."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares are held of record by OrbiMed Genesis Master Fund, L.P. (\"Genesis Master Fund\"). Genesis GP is the general partner of Genesis Master Fund and OrbiMed Advisors is the managing member of Genesis GP. By virtue of such relationships, Genesis GP and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by Genesis Master Fund and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the shares held by Genesis Master Fund."}],"balance_after":114039,"source":{"system":"sec-edgar","filing":"0001209191-20-052339","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000120919120052339/doc4.xml","form_type":"4"}},{"id":3020976,"issuer":{"id":7062,"kind":"organization","name":"PMV Pharmaceuticals, Inc.","symbol":"PMVP"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53130,"kind":"organization","name":"OrbiMed Capital GP V LLC","position":2,"cik":"0001615374","reported_name":"OrbiMed Capital GP V LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":3,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51518,"kind":"person","name":"ORBIMED CAPITAL LLC","position":4,"cik":"0001157524","reported_name":"ORBIMED CAPITAL LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-09-29T20:39:56.000Z","date":"2020-09-29","kind":"exercise","acquired":true,"shares":380133,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The shares of each of the Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and have no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The shares are held of record by OrbiMed Private Investments V, LP (\"OPI V\"). OrbiMed Capital GP V LLC (\"GP V\") is the general partner of OPI V, and OrbiMed Advisors LLC (\"OrbiMed Advisors\"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the managing member of GP V. By virtue of such relationships, GP V and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by OPI V noted above and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"). OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the shares held by OPI V."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"This report on Form 4 is jointly filed by OrbiMed Advisors, GP V, OrbiMed Genesis GP LLC (\"Genesis GP\") and OrbiMed Capital LLC (\"OrbiMed Capital\"). Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose. The Reporting Persons have designated a representative, Peter Thompson, an employee of OrbiMed Advisors, to serve on the Issuer's board of directors."}],"balance_after":6475291,"source":{"system":"sec-edgar","filing":"0001209191-20-052339","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000120919120052339/doc4.xml","form_type":"4"}},{"id":3020975,"issuer":{"id":7062,"kind":"organization","name":"PMV Pharmaceuticals, Inc.","symbol":"PMVP"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53130,"kind":"organization","name":"OrbiMed Capital GP V LLC","position":2,"cik":"0001615374","reported_name":"OrbiMed Capital GP V LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":3,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51518,"kind":"person","name":"ORBIMED CAPITAL LLC","position":4,"cik":"0001157524","reported_name":"ORBIMED CAPITAL LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-09-29T20:39:56.000Z","date":"2020-09-29","kind":"exercise","acquired":true,"shares":518191,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The shares of each of the Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and have no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The shares are held of record by OrbiMed Private Investments V, LP (\"OPI V\"). OrbiMed Capital GP V LLC (\"GP V\") is the general partner of OPI V, and OrbiMed Advisors LLC (\"OrbiMed Advisors\"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the managing member of GP V. By virtue of such relationships, GP V and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by OPI V noted above and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"). OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the shares held by OPI V."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"This report on Form 4 is jointly filed by OrbiMed Advisors, GP V, OrbiMed Genesis GP LLC (\"Genesis GP\") and OrbiMed Capital LLC (\"OrbiMed Capital\"). Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose. The Reporting Persons have designated a representative, Peter Thompson, an employee of OrbiMed Advisors, to serve on the Issuer's board of directors."}],"balance_after":6095158,"source":{"system":"sec-edgar","filing":"0001209191-20-052339","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000120919120052339/doc4.xml","form_type":"4"}},{"id":3020974,"issuer":{"id":7062,"kind":"organization","name":"PMV Pharmaceuticals, Inc.","symbol":"PMVP"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53130,"kind":"organization","name":"OrbiMed Capital GP V LLC","position":2,"cik":"0001615374","reported_name":"OrbiMed Capital GP V LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":3,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51518,"kind":"person","name":"ORBIMED CAPITAL LLC","position":4,"cik":"0001157524","reported_name":"ORBIMED CAPITAL LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-09-29T20:39:56.000Z","date":"2020-09-29","kind":"exercise","acquired":true,"shares":1076891,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The shares of each of the Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and have no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The shares are held of record by OrbiMed Private Investments V, LP (\"OPI V\"). OrbiMed Capital GP V LLC (\"GP V\") is the general partner of OPI V, and OrbiMed Advisors LLC (\"OrbiMed Advisors\"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the managing member of GP V. By virtue of such relationships, GP V and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by OPI V noted above and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"). OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the shares held by OPI V."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"This report on Form 4 is jointly filed by OrbiMed Advisors, GP V, OrbiMed Genesis GP LLC (\"Genesis GP\") and OrbiMed Capital LLC (\"OrbiMed Capital\"). Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose. The Reporting Persons have designated a representative, Peter Thompson, an employee of OrbiMed Advisors, to serve on the Issuer's board of directors."}],"balance_after":5576967,"source":{"system":"sec-edgar","filing":"0001209191-20-052339","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000120919120052339/doc4.xml","form_type":"4"}},{"id":3020973,"issuer":{"id":7062,"kind":"organization","name":"PMV Pharmaceuticals, Inc.","symbol":"PMVP"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53130,"kind":"organization","name":"OrbiMed Capital GP V LLC","position":2,"cik":"0001615374","reported_name":"OrbiMed Capital GP V LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":3,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51518,"kind":"person","name":"ORBIMED CAPITAL LLC","position":4,"cik":"0001157524","reported_name":"ORBIMED CAPITAL LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-09-29T20:39:56.000Z","date":"2020-09-29","kind":"exercise","acquired":true,"shares":4025076,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The shares of each of the Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and have no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The shares are held of record by OrbiMed Private Investments V, LP (\"OPI V\"). OrbiMed Capital GP V LLC (\"GP V\") is the general partner of OPI V, and OrbiMed Advisors LLC (\"OrbiMed Advisors\"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the managing member of GP V. By virtue of such relationships, GP V and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by OPI V noted above and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"). OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the shares held by OPI V."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"This report on Form 4 is jointly filed by OrbiMed Advisors, GP V, OrbiMed Genesis GP LLC (\"Genesis GP\") and OrbiMed Capital LLC (\"OrbiMed Capital\"). Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose. The Reporting Persons have designated a representative, Peter Thompson, an employee of OrbiMed Advisors, to serve on the Issuer's board of directors."}],"balance_after":4500076,"source":{"system":"sec-edgar","filing":"0001209191-20-052339","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000120919120052339/doc4.xml","form_type":"4"}},{"id":3020972,"issuer":{"id":7062,"kind":"organization","name":"PMV Pharmaceuticals, Inc.","symbol":"PMVP"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53130,"kind":"organization","name":"OrbiMed Capital GP V LLC","position":2,"cik":"0001615374","reported_name":"OrbiMed Capital GP V LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":3,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51518,"kind":"person","name":"ORBIMED CAPITAL LLC","position":4,"cik":"0001157524","reported_name":"ORBIMED CAPITAL LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-09-29T20:39:56.000Z","date":"2020-09-25","kind":"purchase","acquired":true,"shares":475000,"price":18,"value":8550000.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The shares are held of record by OrbiMed Private Investments V, LP (\"OPI V\"). OrbiMed Capital GP V LLC (\"GP V\") is the general partner of OPI V, and OrbiMed Advisors LLC (\"OrbiMed Advisors\"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the managing member of GP V. By virtue of such relationships, GP V and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by OPI V noted above and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"). OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the shares held by OPI V."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"This report on Form 4 is jointly filed by OrbiMed Advisors, GP V, OrbiMed Genesis GP LLC (\"Genesis GP\") and OrbiMed Capital LLC (\"OrbiMed Capital\"). Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose. The Reporting Persons have designated a representative, Peter Thompson, an employee of OrbiMed Advisors, to serve on the Issuer's board of directors."}],"balance_after":475000,"source":{"system":"sec-edgar","filing":"0001209191-20-052339","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000120919120052339/doc4.xml","form_type":"4"}},{"id":3028958,"issuer":{"id":6860,"kind":"organization","name":"Adicet Bio, Inc."},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53130,"kind":"organization","name":"OrbiMed Capital GP V LLC","position":2,"cik":"0001615374","reported_name":"OrbiMed Capital GP V LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51517,"kind":"person","name":"OrbiMed Capital GP VI LLC","position":3,"cik":"0001682115","reported_name":"OrbiMed Capital GP VI LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53131,"kind":"organization","name":"OrbiMed Advisors Israel II Ltd","position":4,"cik":"0001682093","reported_name":"OrbiMed Advisors Israel II Ltd","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53132,"kind":"organization","name":"OrbiMed Israel GP II, L.P.","position":5,"cik":"0001682090","reported_name":"OrbiMed Israel GP II, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53133,"kind":"organization","name":"OrbiMed Israel GP Ltd.","position":6,"cik":"0001569590","reported_name":"OrbiMed Israel GP Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53134,"kind":"organization","name":"OrbiMed Israel BioFund GP Limited Partnership","position":7,"cik":"0001569821","reported_name":"OrbiMed Israel BioFund GP Limited Partnership","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-09-18T01:45:55.000Z","date":"2020-09-17","kind":"grant","acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F10","text":"This option is held by Chimovits. 1/36th of the shares of the Issuer's common stock subject to the option shall vest on each of the next thirty-six (36) monthly anniversaries of the grant date, provided that Chimovits remains in continuous service as of the applicable vesting date. Pursuant to agreements with OrbiMed BioFund, OrbiMed Israel GP, OrbiMed Israel GP II, and OrbiMed Israel II, Chimovits is obligated to transfer these securities, or the economic benefit thereof, to OrbiMed BioFund, OrbiMed Israel GP, OrbiMed Israel GP II, and OrbiMed Israel II, which will in turn ensure that such securities or economic benefit are provided to OIP and OIP II."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F10","text":"This option is held by Chimovits. 1/36th of the shares of the Issuer's common stock subject to the option shall vest on each of the next thirty-six (36) monthly anniversaries of the grant date, provided that Chimovits remains in continuous service as of the applicable vesting date. Pursuant to agreements with OrbiMed BioFund, OrbiMed Israel GP, OrbiMed Israel GP II, and OrbiMed Israel II, Chimovits is obligated to transfer these securities, or the economic benefit thereof, to OrbiMed BioFund, OrbiMed Israel GP, OrbiMed Israel GP II, and OrbiMed Israel II, which will in turn ensure that such securities or economic benefit are provided to OIP and OIP II."}],"balance_after":30000,"derivative":{"exercise_price":16.11,"expiration_date":"2030-09-17","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0000947871-20-000738","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787120000738/ownership.xml","form_type":"4"}},{"id":3028957,"issuer":{"id":6860,"kind":"organization","name":"Adicet Bio, Inc."},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53130,"kind":"organization","name":"OrbiMed Capital GP V LLC","position":2,"cik":"0001615374","reported_name":"OrbiMed Capital GP V LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51517,"kind":"person","name":"OrbiMed Capital GP VI LLC","position":3,"cik":"0001682115","reported_name":"OrbiMed Capital GP VI LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53131,"kind":"organization","name":"OrbiMed Advisors Israel II Ltd","position":4,"cik":"0001682093","reported_name":"OrbiMed Advisors Israel II Ltd","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53132,"kind":"organization","name":"OrbiMed Israel GP II, L.P.","position":5,"cik":"0001682090","reported_name":"OrbiMed Israel GP II, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53133,"kind":"organization","name":"OrbiMed Israel GP Ltd.","position":6,"cik":"0001569590","reported_name":"OrbiMed Israel GP Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53134,"kind":"organization","name":"OrbiMed Israel BioFund GP Limited Partnership","position":7,"cik":"0001569821","reported_name":"OrbiMed Israel BioFund GP Limited Partnership","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-09-18T01:45:55.000Z","date":"2020-09-17","kind":"grant","acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"This option is held by Gordon. 1/36th of the shares of the Issuer's common stock subject to the option shall vest on each of the next thirty-six (36) monthly anniversaries of the grant date, provided that Gordon remains in continuous service as of the applicable vesting date. Pursuant to agreements with OrbiMed Advisors, GP V, and GP VI, Gordon is obligated to transfer these securities, or the economic benefit thereof, to OrbiMed Advisors, GP V, and GP VI, which will in turn ensure that such securities or economic benefits are provided to OPI V and OPI VI."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"This option is held by Gordon. 1/36th of the shares of the Issuer's common stock subject to the option shall vest on each of the next thirty-six (36) monthly anniversaries of the grant date, provided that Gordon remains in continuous service as of the applicable vesting date. Pursuant to agreements with OrbiMed Advisors, GP V, and GP VI, Gordon is obligated to transfer these securities, or the economic benefit thereof, to OrbiMed Advisors, GP V, and GP VI, which will in turn ensure that such securities or economic benefits are provided to OPI V and OPI VI."}],"balance_after":30000,"derivative":{"exercise_price":16.11,"expiration_date":"2030-09-17","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0000947871-20-000738","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787120000738/ownership.xml","form_type":"4"}},{"id":3028956,"issuer":{"id":6860,"kind":"organization","name":"Adicet Bio, Inc."},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53130,"kind":"organization","name":"OrbiMed Capital GP V LLC","position":2,"cik":"0001615374","reported_name":"OrbiMed Capital GP V LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51517,"kind":"person","name":"OrbiMed Capital GP VI LLC","position":3,"cik":"0001682115","reported_name":"OrbiMed Capital GP VI LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53131,"kind":"organization","name":"OrbiMed Advisors Israel II Ltd","position":4,"cik":"0001682093","reported_name":"OrbiMed Advisors Israel II Ltd","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53132,"kind":"organization","name":"OrbiMed Israel GP II, L.P.","position":5,"cik":"0001682090","reported_name":"OrbiMed Israel GP II, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53133,"kind":"organization","name":"OrbiMed Israel GP Ltd.","position":6,"cik":"0001569590","reported_name":"OrbiMed Israel GP Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53134,"kind":"organization","name":"OrbiMed Israel BioFund GP Limited Partnership","position":7,"cik":"0001569821","reported_name":"OrbiMed Israel BioFund GP Limited Partnership","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-09-18T01:45:55.000Z","date":"2020-09-15","kind":"grant","acquired":true,"shares":292607,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Received in exchange for 2,359,734 shares of the common stock of Old Adicet on the closing of the Merger, as described in footnote 2."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"This report is being jointly filed by OrbiMed Advisors, OrbiMed GP V, OrbiMed GP VI, OrbiMed Israel GP II, OrbiMed Israel II, OrbiMed BioFund. and OrbiMed Israel GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Persons are a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose. The Reporting Persons have designated Carl L. Gordon (\"Gordon\") and Erez Chimovits (\"Chimovits\") to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Persons, Gordon, or Chimovits is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"These shares of the Issuer's common stock are held of record by OrbiMed Israel Partners II, L.P. (\"OIP II\"). OrbiMed Israel GP II, L.P. (\"OrbiMed Israel GP II\") is the general partner of OIP II, and OrbiMed Advisors Israel II Limited (\"OrbiMed Israel II\") is the general partner of OrbiMed Israel GP II. By virtue of such relationships, OrbiMed Israel GP II and OrbiMed Israel II may be deemed to have voting and investment power with respect to the shares held directly by OIP II noted above and, as a result, may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Exchange Act. OrbiMed Israel II exercises this investment and voting power through a management committee comprised of Gordon, Jonathan T. Silverstein, Nissim Darvish, Anat Naschitz, and Chimovits, each of whom disclaims beneficial ownership of the shares held by OIP II."}],"balance_after":292607,"source":{"system":"sec-edgar","filing":"0000947871-20-000738","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787120000738/ownership.xml","form_type":"4"}},{"id":3028955,"issuer":{"id":6860,"kind":"organization","name":"Adicet Bio, Inc."},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53130,"kind":"organization","name":"OrbiMed Capital GP V LLC","position":2,"cik":"0001615374","reported_name":"OrbiMed Capital GP V LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51517,"kind":"person","name":"OrbiMed Capital GP VI LLC","position":3,"cik":"0001682115","reported_name":"OrbiMed Capital GP VI LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53131,"kind":"organization","name":"OrbiMed Advisors Israel II Ltd","position":4,"cik":"0001682093","reported_name":"OrbiMed Advisors Israel II Ltd","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53132,"kind":"organization","name":"OrbiMed Israel GP II, L.P.","position":5,"cik":"0001682090","reported_name":"OrbiMed Israel GP II, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53133,"kind":"organization","name":"OrbiMed Israel GP Ltd.","position":6,"cik":"0001569590","reported_name":"OrbiMed Israel GP Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53134,"kind":"organization","name":"OrbiMed Israel BioFund GP Limited Partnership","position":7,"cik":"0001569821","reported_name":"OrbiMed Israel BioFund GP Limited Partnership","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-09-18T01:45:55.000Z","date":"2020-09-15","kind":"grant","acquired":true,"shares":902885,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Received in exchange for 7,281,335 shares of the common stock of Old Adicet on the closing of the Merger, as described in footnote 2."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"This report is being jointly filed by OrbiMed Advisors, OrbiMed GP V, OrbiMed GP VI, OrbiMed Israel GP II, OrbiMed Israel II, OrbiMed BioFund. and OrbiMed Israel GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Persons are a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose. The Reporting Persons have designated Carl L. Gordon (\"Gordon\") and Erez Chimovits (\"Chimovits\") to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Persons, Gordon, or Chimovits is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"These shares of the Issuer's common stock are held of record by OrbiMed Israel Partners Limited Partnership (\"OIP\"). OrbiMed Israel BioFund GP Limited Partnership (\"OrbiMed BioFund\") is the general partner of OIP, and OrbiMed Israel GP Ltd. (\"OrbiMed Israel GP\") is the general partner of OrbiMed BioFund. By virtue of such relationships, OrbiMed BioFund and OrbiMed Israel GP may be deemed to have voting and investment power with respect to the shares held directly by OIP noted above and, as a result, may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Exchange Act. OrbiMed Israel GP exercises this investment and voting power through a management committee comprised of Gordon, Jonathan T. Silverstein, Nissim Darvish, Anat Naschitz, and Chimovits, each of whom disclaims beneficial ownership of the shares held by OIP."}],"balance_after":902855,"source":{"system":"sec-edgar","filing":"0000947871-20-000738","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787120000738/ownership.xml","form_type":"4"}},{"id":3028954,"issuer":{"id":6860,"kind":"organization","name":"Adicet Bio, Inc."},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53130,"kind":"organization","name":"OrbiMed Capital GP V LLC","position":2,"cik":"0001615374","reported_name":"OrbiMed Capital GP V LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51517,"kind":"person","name":"OrbiMed Capital GP VI LLC","position":3,"cik":"0001682115","reported_name":"OrbiMed Capital GP VI LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53131,"kind":"organization","name":"OrbiMed Advisors Israel II Ltd","position":4,"cik":"0001682093","reported_name":"OrbiMed Advisors Israel II Ltd","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53132,"kind":"organization","name":"OrbiMed Israel GP II, L.P.","position":5,"cik":"0001682090","reported_name":"OrbiMed Israel GP II, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53133,"kind":"organization","name":"OrbiMed Israel GP Ltd.","position":6,"cik":"0001569590","reported_name":"OrbiMed Israel GP Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53134,"kind":"organization","name":"OrbiMed Israel BioFund GP Limited Partnership","position":7,"cik":"0001569821","reported_name":"OrbiMed Israel BioFund GP Limited Partnership","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-09-18T01:45:55.000Z","date":"2020-09-15","kind":"grant","acquired":true,"shares":4822960,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Received in exchange for 38,894,843 shares of the common stock of Adicet Bio, Inc., (\"Old Adicet\") on the closing of the merger (the \"Merger\") pursuant to the Agreement and Plan of Merger dated April 18, 2020 (the \"Merger Agreement\") by and among the Issuer, Old Adicet and Project Oasis Merger Sub, Inc., a direct, wholly-owned subsidiary of the Issuer, whereby each share of Old Adicet common stock was canceled and automatically converted into .1240 shares of Issuer common stock (the \"Exchange Ratio\"), with fractional shares being eliminated after first being aggregated, as provided in the Merger Agreement. The Issuer was renamed Adicet Bio, Inc. following the closing of the Merger."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These shares of the Issuer's common stock are held of record by OrbiMed Private Investments V, LP (\"OPI V\"). OrbiMed Capital GP V LLC (\"GP V\") is the general partner of OPI V, and OrbiMed Advisors is the managing member of GP V. By virtue of such relationships, GP V and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by OPI V noted above and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Exchange Act. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the Shares held by OPI V."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"This report is being jointly filed by OrbiMed Advisors, OrbiMed GP V, OrbiMed GP VI, OrbiMed Israel GP II, OrbiMed Israel II, OrbiMed BioFund. and OrbiMed Israel GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Persons are a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose. The Reporting Persons have designated Carl L. Gordon (\"Gordon\") and Erez Chimovits (\"Chimovits\") to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Persons, Gordon, or Chimovits is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":4822960,"source":{"system":"sec-edgar","filing":"0000947871-20-000738","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787120000738/ownership.xml","form_type":"4"}},{"id":3052748,"issuer":{"id":1186,"kind":"organization","name":"Inspire Medical Systems, Inc.","symbol":"INSP"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":53130,"kind":"organization","name":"OrbiMed Capital GP V LLC","position":2,"cik":"0001615374","reported_name":"OrbiMed Capital GP V LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, $0.001 par value","published_at":"2020-08-19T21:24:08.000Z","date":"2020-08-18","kind":"sale","acquired":false,"shares":43543,"price":108.54,"value":4726157.22,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"These shares of the Issuer's common stock were sold in a block order at a price of $108.54."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares of the Issuer's common stock are held of record by OrbiMed Private Investments V, LP (\"OPI V\"). OrbiMed Capital GP V LLC (\"GP V\") is the general partner of OPI V, and OrbiMed Advisors LLC (\"Advisors\"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the managing member of GP V. By virtue of such relationships, GP V and Advisors may be deemed to have voting and investment power with respect to the securities held by OPI V noted above and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"). Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the Shares held by OPI V."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"This report on Form 4 is jointly filed by GP V and Advisors. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated a representative, currently Chau Khuong (\"Khuong\"), an employee of Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act, or for any other purposes."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000947871-20-000699","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787120000699/ownership.xml","form_type":"4"}},{"id":3052747,"issuer":{"id":1186,"kind":"organization","name":"Inspire Medical Systems, Inc.","symbol":"INSP"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":53130,"kind":"organization","name":"OrbiMed Capital GP V LLC","position":2,"cik":"0001615374","reported_name":"OrbiMed Capital GP V LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, $0.001 par value","published_at":"2020-08-19T21:24:08.000Z","date":"2020-08-17","kind":"sale","acquired":false,"shares":94900,"price":107.49,"value":10200801.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"These shares of the Issuer's common stock were sold in a block order at a price of $107.49."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares of the Issuer's common stock are held of record by OrbiMed Private Investments V, LP (\"OPI V\"). OrbiMed Capital GP V LLC (\"GP V\") is the general partner of OPI V, and OrbiMed Advisors LLC (\"Advisors\"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the managing member of GP V. By virtue of such relationships, GP V and Advisors may be deemed to have voting and investment power with respect to the securities held by OPI V noted above and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"). Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the Shares held by OPI V."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"This report on Form 4 is jointly filed by GP V and Advisors. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated a representative, currently Chau Khuong (\"Khuong\"), an employee of Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act, or for any other purposes."}],"balance_after":43543,"source":{"system":"sec-edgar","filing":"0000947871-20-000699","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787120000699/ownership.xml","form_type":"4"}},{"id":3057592,"issuer":{"id":1186,"kind":"organization","name":"Inspire Medical Systems, Inc.","symbol":"INSP"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":53130,"kind":"organization","name":"OrbiMed Capital GP V LLC","position":2,"cik":"0001615374","reported_name":"OrbiMed Capital GP V LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, $0.001 par value","published_at":"2020-08-14T21:19:11.000Z","date":"2020-08-14","kind":"sale","acquired":false,"shares":20257,"price":109.03,"value":2208620.71,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"These shares of the Issuer's common stock were sold in a block order at a price of $109.03."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares of the Issuer's common stock are held of record by OrbiMed Private Investments V, LP (\"OPI V\"). OrbiMed Capital GP V LLC (\"GP V\") is the general partner of OPI V, and OrbiMed Advisors LLC (\"Advisors\"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the managing member of GP V. By virtue of such relationships, GP V and Advisors may be deemed to have voting and investment power with respect to the securities held by OPI V noted above and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"). Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the Shares held by OPI V."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"This report on Form 4 is jointly filed by GP V and Advisors. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated a representative, currently Chau Khuong (\"Khuong\"), an employee of Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act, or for any other purposes."}],"balance_after":138443,"source":{"system":"sec-edgar","filing":"0000947871-20-000684","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787120000684/ownership.xml","form_type":"4"}},{"id":3057591,"issuer":{"id":1186,"kind":"organization","name":"Inspire Medical Systems, Inc.","symbol":"INSP"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":53130,"kind":"organization","name":"OrbiMed Capital GP V LLC","position":2,"cik":"0001615374","reported_name":"OrbiMed Capital GP V LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, $0.001 par value","published_at":"2020-08-14T21:19:11.000Z","date":"2020-08-13","kind":"sale","acquired":false,"shares":29251,"price":109.93,"value":3215562.43,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"These shares of the Issuer's common stock were sold in a block order at a price of $109.93."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares of the Issuer's common stock are held of record by OrbiMed Private Investments V, LP (\"OPI V\"). OrbiMed Capital GP V LLC (\"GP V\") is the general partner of OPI V, and OrbiMed Advisors LLC (\"Advisors\"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the managing member of GP V. By virtue of such relationships, GP V and Advisors may be deemed to have voting and investment power with respect to the securities held by OPI V noted above and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"). Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the Shares held by OPI V."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"This report on Form 4 is jointly filed by GP V and Advisors. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated a representative, currently Chau Khuong (\"Khuong\"), an employee of Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act, or for any other purposes."}],"balance_after":158500,"source":{"system":"sec-edgar","filing":"0000947871-20-000684","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787120000684/ownership.xml","form_type":"4"}},{"id":3057590,"issuer":{"id":1186,"kind":"organization","name":"Inspire Medical Systems, Inc.","symbol":"INSP"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":53130,"kind":"organization","name":"OrbiMed Capital GP V LLC","position":2,"cik":"0001615374","reported_name":"OrbiMed Capital GP V LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, $0.001 par value","published_at":"2020-08-14T21:19:11.000Z","date":"2020-08-12","kind":"sale","acquired":false,"shares":42679,"price":107.45,"value":4585858.55,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"These shares of the Issuer's common stock were sold in a block order at a price of $107.45."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares of the Issuer's common stock are held of record by OrbiMed Private Investments V, LP (\"OPI V\"). OrbiMed Capital GP V LLC (\"GP V\") is the general partner of OPI V, and OrbiMed Advisors LLC (\"Advisors\"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the managing member of GP V. By virtue of such relationships, GP V and Advisors may be deemed to have voting and investment power with respect to the securities held by OPI V noted above and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"). Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the Shares held by OPI V."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"This report on Form 4 is jointly filed by GP V and Advisors. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated a representative, currently Chau Khuong (\"Khuong\"), an employee of Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act, or for any other purposes."}],"balance_after":187751,"source":{"system":"sec-edgar","filing":"0000947871-20-000684","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787120000684/ownership.xml","form_type":"4"}},{"id":3062322,"issuer":{"id":1186,"kind":"organization","name":"Inspire Medical Systems, Inc.","symbol":"INSP"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":53130,"kind":"organization","name":"OrbiMed Capital GP V LLC","position":2,"cik":"0001615374","reported_name":"OrbiMed Capital GP V LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, $0.001 par value","published_at":"2020-08-11T22:23:36.000Z","date":"2020-08-11","kind":"sale","acquired":false,"shares":39877,"price":105.78,"value":4218189.06,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"These shares of the Issuer's common stock were sold in a block order at a price of $105.78."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares of the Issuer's common stock are held of record by OrbiMed Private Investments V, LP (\"OPI V\"). OrbiMed Capital GP V LLC (\"GP V\") is the general partner of OPI V, and OrbiMed Advisors LLC (\"Advisors\"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the managing member of GP V. By virtue of such relationships, GP V and Advisors may be deemed to have voting and investment power with respect to the securities held by OPI V noted above and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"). Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the Shares held by OPI V."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"This report on Form 4 is jointly filed by GP V and Advisors. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated a representative, currently Chau Khuong (\"Khuong\"), an employee of Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act, or for any other purposes."}],"balance_after":230430,"source":{"system":"sec-edgar","filing":"0000947871-20-000676","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787120000676/ownership.xml","form_type":"4"}},{"id":3062321,"issuer":{"id":1186,"kind":"organization","name":"Inspire Medical Systems, Inc.","symbol":"INSP"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":53130,"kind":"organization","name":"OrbiMed Capital GP V LLC","position":2,"cik":"0001615374","reported_name":"OrbiMed Capital GP V LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, $0.001 par value","published_at":"2020-08-11T22:23:36.000Z","date":"2020-08-10","kind":"sale","acquired":false,"shares":47700,"price":105.23,"value":5019471.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"These shares of the Issuer's common stock were sold in two separate block orders, each at a price of $105.23."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares of the Issuer's common stock are held of record by OrbiMed Private Investments V, LP (\"OPI V\"). OrbiMed Capital GP V LLC (\"GP V\") is the general partner of OPI V, and OrbiMed Advisors LLC (\"Advisors\"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the managing member of GP V. By virtue of such relationships, GP V and Advisors may be deemed to have voting and investment power with respect to the securities held by OPI V noted above and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"). Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the Shares held by OPI V."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"This report on Form 4 is jointly filed by GP V and Advisors. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated a representative, currently Chau Khuong (\"Khuong\"), an employee of Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act, or for any other purposes."}],"balance_after":270307,"source":{"system":"sec-edgar","filing":"0000947871-20-000676","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787120000676/ownership.xml","form_type":"4"}},{"id":3062320,"issuer":{"id":1186,"kind":"organization","name":"Inspire Medical Systems, Inc.","symbol":"INSP"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":53130,"kind":"organization","name":"OrbiMed Capital GP V LLC","position":2,"cik":"0001615374","reported_name":"OrbiMed Capital GP V LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, $0.001 par value","published_at":"2020-08-11T22:23:36.000Z","date":"2020-08-07","kind":"sale","acquired":false,"shares":28993,"price":106.18,"value":3078476.74,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"These shares of the Issuer's common stock were sold in a block order at a price of $106.18."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares of the Issuer's common stock are held of record by OrbiMed Private Investments V, LP (\"OPI V\"). OrbiMed Capital GP V LLC (\"GP V\") is the general partner of OPI V, and OrbiMed Advisors LLC (\"Advisors\"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the managing member of GP V. By virtue of such relationships, GP V and Advisors may be deemed to have voting and investment power with respect to the securities held by OPI V noted above and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"). Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the Shares held by OPI V."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"This report on Form 4 is jointly filed by GP V and Advisors. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated a representative, currently Chau Khuong (\"Khuong\"), an employee of Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act, or for any other purposes."}],"balance_after":318007,"source":{"system":"sec-edgar","filing":"0000947871-20-000676","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787120000676/ownership.xml","form_type":"4"}},{"id":3102169,"issuer":{"id":5614,"kind":"organization","name":"Compass Therapeutics, Inc.","symbol":"CMPX"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53130,"kind":"organization","name":"OrbiMed Capital GP V LLC","position":2,"cik":"0001615374","reported_name":"OrbiMed Capital GP V LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-06-24T01:36:59.000Z","date":"2020-06-19","kind":"purchase","acquired":true,"shares":1455132,"price":5,"value":7275660.0,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"These shares are held of record by OrbiMed Private Investments V-KA, LP (\"OPI V-KA\"). OrbiMed Capital GP V LLC (\"OrbiMed GP V\") is the general partner of OPI V-KA and OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the managing member of OrbiMed GP V. By virtue of such relationships, OrbiMed GP V and OrbiMed Advisors may be deemed to have voting and investment power over the shares held by OPI V-KA and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the shares held by OPI V-KA."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"This report on Form 4 is jointly filed by OrbiMed Advisors and OrbiMed GP V. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated a representative, Carl L. Gordon (\"Gordon\"), a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":12714404,"source":{"system":"sec-edgar","filing":"0001213900-20-015635","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000121390020015635/ownership.xml","form_type":"4"}},{"id":3218427,"issuer":{"id":1186,"kind":"organization","name":"Inspire Medical Systems, Inc.","symbol":"INSP"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":53130,"kind":"organization","name":"OrbiMed Capital GP V LLC","position":2,"cik":"0001615374","reported_name":"OrbiMed Capital GP V LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, $0.001 par value","published_at":"2020-03-10T21:06:53.000Z","date":"2020-03-06","kind":"sale","acquired":false,"shares":500000,"price":83.52,"value":41760000.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"These shares of the Issuer's common stock were sold in two separate block orders, each at a price of $83.52."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares of the Issuer's common stock are held of record by OPI V. OrbiMed Capital GP V LLC (\"GP V\") is the sole general partner of OPI V, and OrbiMed Advisors LLC (\"Advisors\"), a registered adviser under the Investment Advisors Act of 1940, as amended, is the sole managing member of GP V. By virtue of such relationships, GP V and Advisors may be deemed to have voting and investment power with respect to the securities held by OPI V noted above and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"). Advisors exercised this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the Shares held by OPI V."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"This report on Form 4 is jointly filed by GP V and Advisors. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated a representative, currently Chau Khuong (\"Khuong\"), an employee of Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act, or for any other purposes."}],"balance_after":347000,"source":{"system":"sec-edgar","filing":"0000947871-20-000208","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787120000208/ownership.xml","form_type":"4"}},{"id":3225088,"issuer":{"id":1186,"kind":"organization","name":"Inspire Medical Systems, Inc.","symbol":"INSP"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":53130,"kind":"organization","name":"OrbiMed Capital GP V LLC","position":2,"cik":"0001615374","reported_name":"OrbiMed Capital GP V LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, $0.001 par value","published_at":"2020-03-05T23:34:06.000Z","date":"2020-03-03","kind":"sale","acquired":false,"shares":400000,"price":84.42,"value":33768000.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"These shares of the Issuer's common stock were sold in a block order at a price of $84.42."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares of the Issuer's common stock are held of record by OPI V. OrbiMed Capital GP V LLC (\"GP V\") is the sole general partner of OPI V, and OrbiMed Advisors LLC (\"Advisors\"), a registered adviser under the Investment Advisors Act of 1940, as amended, is the sole managing member of GP V. By virtue of such relationships, GP V and Advisors may be deemed to have voting and investment power with respect to the securities held by OPI V noted above and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"). Advisors exercised this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the Shares held by OPI V."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"This report on Form 4 is jointly filed by GP V and Advisors. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated a representative, currently Chau Khuong (\"Khuong\"), an employee of Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act, or for any other purposes."}],"balance_after":847000,"source":{"system":"sec-edgar","filing":"0000947871-20-000192","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787120000192/ownership.xml","form_type":"4"}},{"id":3225087,"issuer":{"id":1186,"kind":"organization","name":"Inspire Medical Systems, Inc.","symbol":"INSP"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":53130,"kind":"organization","name":"OrbiMed Capital GP V LLC","position":2,"cik":"0001615374","reported_name":"OrbiMed Capital GP V LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, $0.001 par value","published_at":"2020-03-05T23:34:06.000Z","date":"2020-03-03","kind":"sale","acquired":false,"shares":25000,"price":84.55,"value":2113750.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"These shares of the Issuer's common stock were sold in a block order at a price of $84.55."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares of the Issuer's common stock are held of record by OPI V. OrbiMed Capital GP V LLC (\"GP V\") is the sole general partner of OPI V, and OrbiMed Advisors LLC (\"Advisors\"), a registered adviser under the Investment Advisors Act of 1940, as amended, is the sole managing member of GP V. By virtue of such relationships, GP V and Advisors may be deemed to have voting and investment power with respect to the securities held by OPI V noted above and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"). Advisors exercised this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the Shares held by OPI V."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"This report on Form 4 is jointly filed by GP V and Advisors. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated a representative, currently Chau Khuong (\"Khuong\"), an employee of Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act, or for any other purposes."}],"balance_after":1247000,"source":{"system":"sec-edgar","filing":"0000947871-20-000192","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787120000192/ownership.xml","form_type":"4"}},{"id":3225086,"issuer":{"id":1186,"kind":"organization","name":"Inspire Medical Systems, Inc.","symbol":"INSP"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":53130,"kind":"organization","name":"OrbiMed Capital GP V LLC","position":2,"cik":"0001615374","reported_name":"OrbiMed Capital GP V LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, $0.001 par value","published_at":"2020-03-05T23:34:06.000Z","date":"2020-03-03","kind":"sale","acquired":false,"shares":75000,"price":83.21,"value":6240750.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"These shares of the Issuer's common stock were sold in a block order at a price of $83.21."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares of the Issuer's common stock are held of record by OPI V. OrbiMed Capital GP V LLC (\"GP V\") is the sole general partner of OPI V, and OrbiMed Advisors LLC (\"Advisors\"), a registered adviser under the Investment Advisors Act of 1940, as amended, is the sole managing member of GP V. By virtue of such relationships, GP V and Advisors may be deemed to have voting and investment power with respect to the securities held by OPI V noted above and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"). Advisors exercised this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the Shares held by OPI V."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"This report on Form 4 is jointly filed by GP V and Advisors. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated a representative, currently Chau Khuong (\"Khuong\"), an employee of Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act, or for any other purposes."}],"balance_after":1272000,"source":{"system":"sec-edgar","filing":"0000947871-20-000192","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787120000192/ownership.xml","form_type":"4"}},{"id":3343930,"issuer":{"id":122050,"kind":"organization","name":"Tricida, Inc.","symbol":"TCDA"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53130,"kind":"organization","name":"OrbiMed Capital GP V LLC","position":2,"cik":"0001615374","reported_name":"OrbiMed Capital GP V LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-12-12T22:20:10.000Z","date":"2019-12-11","kind":"sale","acquired":false,"shares":1500000,"price":40,"value":60000000.0,"ownership":{"direct":false,"nature":"By OrbiMed Private Investments V, LP"},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"These securities are held of record by OrbiMed Private Investments V, LP (\"OPI V\"). OrbiMed Capital GP V LLC (\"GP V\") is the sole general partner of OPI V, and OrbiMed Advisors LLC (\"Advisors\"), a registered adviser under the Investment Advisors Act of 1940, as amended, is the sole managing member of GP V. By virtue of such relationships, GP V and Advisors may be deemed to have voting and investment power with respect to the securities held by OPI V noted above and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"). Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the Shares held by OPI V."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These securities are held of record by OrbiMed Private Investments V, LP (\"OPI V\"). OrbiMed Capital GP V LLC (\"GP V\") is the sole general partner of OPI V, and OrbiMed Advisors LLC (\"Advisors\"), a registered adviser under the Investment Advisors Act of 1940, as amended, is the sole managing member of GP V. By virtue of such relationships, GP V and Advisors may be deemed to have voting and investment power with respect to the securities held by OPI V noted above and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"). Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the Shares held by OPI V."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"This report on Form 4 is jointly filed by GP V and Advisors. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated a representative, David P. Bonita (\"Bonita\"), an employee of Advisors, to serve on the Company's board of directors. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act, or for any other purposes."}],"balance_after":9614280,"source":{"system":"sec-edgar","filing":"0000947871-19-000959","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787119000959/ownership.xml","form_type":"4"}},{"id":3356786,"issuer":{"id":1186,"kind":"organization","name":"Inspire Medical Systems, Inc.","symbol":"INSP"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":53130,"kind":"organization","name":"OrbiMed Capital GP V LLC","position":2,"cik":"0001615374","reported_name":"OrbiMed Capital GP V LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, $0.001 par value","published_at":"2019-11-29T16:56:17.000Z","date":"2019-11-27","kind":"sale","acquired":false,"shares":2306,"price":72.13,"value":166331.78,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a Rule 10b5-1 trading plan established by OrbiMed Private Investments V, LP (\"OPI V\") on September 13, 2019."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price recorded in column 4 is a weighted average price. These Shares were sold in multiple transactions at prices ranging from $72.10 to $72.25, inclusive. Upon request, the Reporting Persons undertake to provide the Issuer, any security holder of the Issuer, or the SEC full information regarding the Shares purchased at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"These securities are held of record by OPI V. OrbiMed Capital GP V LLC (\"GP V\") is the sole general partner of OPI V, and OrbiMed Advisors LLC (\"Advisors\"), a registered adviser under the Investment Advisors Act of 1940, as amended, is the sole managing member of GP V. By virtue of such relationships, GP V and Advisors may be deemed to have voting and investment power with respect to the securities held by OPI V noted above and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"). Advisors exercised this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the Shares held by OPI V."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"This report on Form 4 is jointly filed by GP V and Advisors. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated a representative, currently Chau Khuong, an employee of Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act, or for any other purposes."}],"balance_after":1348326,"source":{"system":"sec-edgar","filing":"0000947871-19-000876","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787119000876/ownership.xml","form_type":"4"}},{"id":3356785,"issuer":{"id":1186,"kind":"organization","name":"Inspire Medical Systems, Inc.","symbol":"INSP"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":53130,"kind":"organization","name":"OrbiMed Capital GP V LLC","position":2,"cik":"0001615374","reported_name":"OrbiMed Capital GP V LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, $0.001 par value","published_at":"2019-11-29T16:56:17.000Z","date":"2019-11-27","kind":"sale","acquired":false,"shares":47981,"price":71.67,"value":3438798.27,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a Rule 10b5-1 trading plan established by OrbiMed Private Investments V, LP (\"OPI V\") on September 13, 2019."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price recorded in column 4 is a weighted average price. These Shares were sold in multiple transactions at prices ranging from $71.10 to $72.08, inclusive. Upon request, the Reporting Persons undertake to provide the Issuer, any security holder of the Issuer, or the SEC full information regarding the Shares purchased at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"These securities are held of record by OPI V. OrbiMed Capital GP V LLC (\"GP V\") is the sole general partner of OPI V, and OrbiMed Advisors LLC (\"Advisors\"), a registered adviser under the Investment Advisors Act of 1940, as amended, is the sole managing member of GP V. By virtue of such relationships, GP V and Advisors may be deemed to have voting and investment power with respect to the securities held by OPI V noted above and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"). Advisors exercised this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the Shares held by OPI V."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"This report on Form 4 is jointly filed by GP V and Advisors. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated a representative, currently Chau Khuong, an employee of Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act, or for any other purposes."}],"balance_after":1350632,"source":{"system":"sec-edgar","filing":"0000947871-19-000876","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787119000876/ownership.xml","form_type":"4"}},{"id":3356784,"issuer":{"id":1186,"kind":"organization","name":"Inspire Medical Systems, Inc.","symbol":"INSP"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":53130,"kind":"organization","name":"OrbiMed Capital GP V LLC","position":2,"cik":"0001615374","reported_name":"OrbiMed Capital GP V LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, $0.001 par value","published_at":"2019-11-29T16:56:17.000Z","date":"2019-11-27","kind":"sale","acquired":false,"shares":3100,"price":70.6,"value":218860.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a Rule 10b5-1 trading plan established by OrbiMed Private Investments V, LP (\"OPI V\") on September 13, 2019."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price recorded in column 4 is a weighted average price. These Shares were sold in multiple transactions at prices ranging from $70.08 to $71.03, inclusive. Upon request, the Reporting Persons undertake to provide the Issuer, any security holder of the Issuer, or the SEC full information regarding the Shares purchased at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"These securities are held of record by OPI V. OrbiMed Capital GP V LLC (\"GP V\") is the sole general partner of OPI V, and OrbiMed Advisors LLC (\"Advisors\"), a registered adviser under the Investment Advisors Act of 1940, as amended, is the sole managing member of GP V. By virtue of such relationships, GP V and Advisors may be deemed to have voting and investment power with respect to the securities held by OPI V noted above and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"). Advisors exercised this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the Shares held by OPI V."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"This report on Form 4 is jointly filed by GP V and Advisors. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated a representative, currently Chau Khuong, an employee of Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act, or for any other purposes."}],"balance_after":1398613,"source":{"system":"sec-edgar","filing":"0000947871-19-000876","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787119000876/ownership.xml","form_type":"4"}},{"id":3356783,"issuer":{"id":1186,"kind":"organization","name":"Inspire Medical Systems, Inc.","symbol":"INSP"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":53130,"kind":"organization","name":"OrbiMed Capital GP V LLC","position":2,"cik":"0001615374","reported_name":"OrbiMed Capital GP V LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, $0.001 par value","published_at":"2019-11-29T16:56:17.000Z","date":"2019-11-26","kind":"sale","acquired":false,"shares":50478,"price":70.16,"value":3541536.48,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a Rule 10b5-1 trading plan established by OrbiMed Private Investments V, LP (\"OPI V\") on September 13, 2019."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price recorded in column 4 is a weighted average price. These Shares were sold in multiple transactions at prices ranging from $70.00 to $70.76, inclusive. Upon request, the Reporting Persons undertake to provide the Issuer, any security holder of the Issuer, or the SEC full information regarding the Shares purchased at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"These securities are held of record by OPI V. OrbiMed Capital GP V LLC (\"GP V\") is the sole general partner of OPI V, and OrbiMed Advisors LLC (\"Advisors\"), a registered adviser under the Investment Advisors Act of 1940, as amended, is the sole managing member of GP V. By virtue of such relationships, GP V and Advisors may be deemed to have voting and investment power with respect to the securities held by OPI V noted above and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"). Advisors exercised this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the Shares held by OPI V."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"This report on Form 4 is jointly filed by GP V and Advisors. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated a representative, currently Chau Khuong, an employee of Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act, or for any other purposes."}],"balance_after":1401713,"source":{"system":"sec-edgar","filing":"0000947871-19-000876","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787119000876/ownership.xml","form_type":"4"}},{"id":3356782,"issuer":{"id":1186,"kind":"organization","name":"Inspire Medical Systems, Inc.","symbol":"INSP"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":53130,"kind":"organization","name":"OrbiMed Capital GP V LLC","position":2,"cik":"0001615374","reported_name":"OrbiMed Capital GP V LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, $0.001 par value","published_at":"2019-11-29T16:56:17.000Z","date":"2019-11-26","kind":"sale","acquired":false,"shares":20135,"price":69.55,"value":1400389.25,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a Rule 10b5-1 trading plan established by OrbiMed Private Investments V, LP (\"OPI V\") on September 13, 2019."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price recorded in column 4 is a weighted average price. These shares of the Issuer's common stock (\"Shares\") were sold in multiple transactions at prices ranging from $69.00 to $69.99, inclusive. Upon request, the Reporting Persons undertake to provide the Issuer, any security holder of the Issuer, or the Securities and Exchange Commission (the \"SEC\") full information regarding the Shares purchased at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"These securities are held of record by OPI V. OrbiMed Capital GP V LLC (\"GP V\") is the sole general partner of OPI V, and OrbiMed Advisors LLC (\"Advisors\"), a registered adviser under the Investment Advisors Act of 1940, as amended, is the sole managing member of GP V. By virtue of such relationships, GP V and Advisors may be deemed to have voting and investment power with respect to the securities held by OPI V noted above and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"). Advisors exercised this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the Shares held by OPI V."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"This report on Form 4 is jointly filed by GP V and Advisors. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated a representative, currently Chau Khuong, an employee of Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act, or for any other purposes."}],"balance_after":1452191,"source":{"system":"sec-edgar","filing":"0000947871-19-000876","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787119000876/ownership.xml","form_type":"4"}},{"id":3443776,"issuer":{"id":4839,"kind":"organization","name":"Corvus Pharmaceuticals, Inc."},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53130,"kind":"organization","name":"OrbiMed Capital GP V LLC","position":2,"cik":"0001615374","reported_name":"OrbiMed Capital GP V LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, $0.0001 par value","published_at":"2019-08-08T20:59:05.000Z","date":"2019-08-06","kind":"purchase","acquired":true,"shares":142656,"price":3.51,"value":500722.56,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares of the Issuer's common stock (\"Shares\") were purchased in multiple transactions at prices ranging from $3.42 to $3.52 inclusive. Upon request, the Reporting Persons undertakes to provide the Issuer, any security holder of the Issuer, or the Securities and Exchange Commission (the \"SEC\") full information regarding the Shares purchased at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by OrbiMed Private Investments V, LP (\"OPI V\"). OrbiMed Capital GP V LLC (\"GP V\") is the sole general partner of OPI V, and OrbiMed Advisors LLC (\"Advisors\"), a registered adviser under the Investment Advisors Act of 1940, as amended, is the sole managing member of GP V. By virtue of such relationships, GP V and Advisors may be deemed to have voting and investment power with respect to the securities held by OPI V noted above and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"). Advisors exercised this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the Shares held by OPI V."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"This report on Form 4 is jointly filed by GP V and Advisors. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated a representative, currently Peter A. Thompson, an employee of Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act, or for any other purposes."}],"balance_after":6767584,"source":{"system":"sec-edgar","filing":"0000947871-19-000571","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787119000571/ownership.xml","form_type":"4"}},{"id":3474992,"issuer":{"id":4839,"kind":"organization","name":"Corvus Pharmaceuticals, Inc."},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53130,"kind":"organization","name":"OrbiMed Capital GP V LLC","position":2,"cik":"0001615374","reported_name":"OrbiMed Capital GP V LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, $0.0001 par value","published_at":"2019-07-01T22:15:53.000Z","date":"2019-07-01","kind":"purchase","acquired":true,"shares":59243,"price":3.91,"value":231640.13,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"These Shares were purchased in a block order at a price of $3.91."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These securities are held of record by OrbiMed Private Investments V, LP (\"OPI V\"). OrbiMed Capital GP V LLC (\"GP V\") is the sole general partner of OPI V, and OrbiMed Advisors LLC (\"Advisors\"), a registered adviser under the Investment Advisors Act of 1940, as amended, is the sole managing member of GP V. By virtue of such relationships, GP V and Advisors may be deemed to have voting and investment power with respect to the securities held by OPI V noted above and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"). Advisors exercised this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the Shares held by OPI V."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"This report on Form 4 is jointly filed by GP V and Advisors. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated a representative, currently Peter A. Thompson, an employee of Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act, or for any other purposes."}],"balance_after":6624928,"source":{"system":"sec-edgar","filing":"0000947871-19-000486","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787119000486/ownership.xml","form_type":"4"}},{"id":3474991,"issuer":{"id":4839,"kind":"organization","name":"Corvus Pharmaceuticals, Inc."},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53130,"kind":"organization","name":"OrbiMed Capital GP V LLC","position":2,"cik":"0001615374","reported_name":"OrbiMed Capital GP V LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, $0.0001 par value","published_at":"2019-07-01T22:15:53.000Z","date":"2019-06-28","kind":"purchase","acquired":true,"shares":565178,"price":3.72,"value":2102462.16,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"These Shares were purchased in a block order at a price of $3.72."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These securities are held of record by OrbiMed Private Investments V, LP (\"OPI V\"). OrbiMed Capital GP V LLC (\"GP V\") is the sole general partner of OPI V, and OrbiMed Advisors LLC (\"Advisors\"), a registered adviser under the Investment Advisors Act of 1940, as amended, is the sole managing member of GP V. By virtue of such relationships, GP V and Advisors may be deemed to have voting and investment power with respect to the securities held by OPI V noted above and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"). Advisors exercised this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the Shares held by OPI V."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"This report on Form 4 is jointly filed by GP V and Advisors. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated a representative, currently Peter A. Thompson, an employee of Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act, or for any other purposes."}],"balance_after":6565685,"source":{"system":"sec-edgar","filing":"0000947871-19-000486","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787119000486/ownership.xml","form_type":"4"}},{"id":3474990,"issuer":{"id":4839,"kind":"organization","name":"Corvus Pharmaceuticals, Inc."},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53130,"kind":"organization","name":"OrbiMed Capital GP V LLC","position":2,"cik":"0001615374","reported_name":"OrbiMed Capital GP V LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, $0.0001 par value","published_at":"2019-07-01T22:15:53.000Z","date":"2019-06-27","kind":"purchase","acquired":true,"shares":32923,"price":3.34,"value":109962.82,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"These shares of the Issuer's common stock (\"Shares\") were purchased in a block order at a price of $3.34."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These securities are held of record by OrbiMed Private Investments V, LP (\"OPI V\"). OrbiMed Capital GP V LLC (\"GP V\") is the sole general partner of OPI V, and OrbiMed Advisors LLC (\"Advisors\"), a registered adviser under the Investment Advisors Act of 1940, as amended, is the sole managing member of GP V. By virtue of such relationships, GP V and Advisors may be deemed to have voting and investment power with respect to the securities held by OPI V noted above and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"). Advisors exercised this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the Shares held by OPI V."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"This report on Form 4 is jointly filed by GP V and Advisors. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated a representative, currently Peter A. Thompson, an employee of Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act, or for any other purposes."}],"balance_after":6000507,"source":{"system":"sec-edgar","filing":"0000947871-19-000486","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787119000486/ownership.xml","form_type":"4"}},{"id":3561837,"issuer":{"id":122050,"kind":"organization","name":"Tricida, Inc.","symbol":"TCDA"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53130,"kind":"organization","name":"OrbiMed Capital GP V LLC","position":2,"cik":"0001615374","reported_name":"OrbiMed Capital GP V LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-04-05T19:24:00.000Z","date":"2019-04-03","kind":"purchase","acquired":true,"shares":225000,"price":36,"value":8100000.0,"ownership":{"direct":false,"nature":"By OrbiMed Private Investments V, LP"},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"These securities are held of record by OrbiMed Private Investments V, LP (\"OPI V\"). OrbiMed Capital GP V LLC (\"GP V\") is the sole general partner of OPI V, and OrbiMed Advisors LLC (\"Advisors\"), a registered adviser under the Investment Advisors Act of 1940, as amended, is the sole managing member of GP V. By virtue of such relationships, GP V and Advisors may be deemed to have voting and investment power with respect to the securities held by OPI V noted above and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"). Advisors exercised this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the Shares held by OPI V."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These securities are held of record by OrbiMed Private Investments V, LP (\"OPI V\"). OrbiMed Capital GP V LLC (\"GP V\") is the sole general partner of OPI V, and OrbiMed Advisors LLC (\"Advisors\"), a registered adviser under the Investment Advisors Act of 1940, as amended, is the sole managing member of GP V. By virtue of such relationships, GP V and Advisors may be deemed to have voting and investment power with respect to the securities held by OPI V noted above and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"). Advisors exercised this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the Shares held by OPI V."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"This report on Form 4 is jointly filed by GP V and Advisors. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated a representative, David P. Bonita, an employee of Advisors, to serve on the Company's board of directors. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act, or for any other purposes."}],"balance_after":11114280,"source":{"system":"sec-edgar","filing":"0000947871-19-000271","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787119000271/ownership.xml","form_type":"4"}},{"id":3602693,"issuer":{"id":1186,"kind":"organization","name":"Inspire Medical Systems, Inc.","symbol":"INSP"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":53130,"kind":"organization","name":"OrbiMed Capital GP V LLC","position":2,"cik":"0001615374","reported_name":"OrbiMed Capital GP V LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, $0.001 par value","published_at":"2019-03-12T01:30:18.000Z","date":"2019-03-08","kind":"sale","acquired":false,"shares":290231,"price":57.75,"value":16760840.25,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"These Shares were sold in a block order at a price of $57.75."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held of record by OrbiMed Private Investments V, LP (\"OPI V\"). OrbiMed Capital GP V LLC (\"GP V\") is the sole general partner of OPI V, and OrbiMed Advisors LLC (\"Advisors\"), a registered adviser under the Investment Advisors Act of 1940, as amended, is the sole managing member of GP V. By virtue of such relationships, GP V and Advisors may be deemed to have voting and investment power with respect to the securities held by OPI V noted above and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"). Advisors exercised this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the Shares held by OPI V."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"This report on Form 4 is jointly filed by GP V and Advisors. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated a representative, currently Chau Khuong, an employee of Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act, or for any other purposes."}],"balance_after":1471725,"source":{"system":"sec-edgar","filing":"0000947871-19-000201","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787119000201/ownership.xml","form_type":"4"}},{"id":3602692,"issuer":{"id":1186,"kind":"organization","name":"Inspire Medical Systems, Inc.","symbol":"INSP"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":53130,"kind":"organization","name":"OrbiMed Capital GP V LLC","position":2,"cik":"0001615374","reported_name":"OrbiMed Capital GP V LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, $0.001 par value","published_at":"2019-03-12T01:30:18.000Z","date":"2019-03-07","kind":"sale","acquired":false,"shares":68218,"price":55.01,"value":3752672.18,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares of the Issuer's common stock (\"Shares\") were sold in multiple transactions at prices ranging from $54.89 to $55.26 inclusive. Upon request, the Reporting Persons undertakes to provide the Issuer, any security holder of the Issuer, or the Securities and Exchange Commission (the \"SEC\") full information regarding the Shares purchased at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held of record by OrbiMed Private Investments V, LP (\"OPI V\"). OrbiMed Capital GP V LLC (\"GP V\") is the sole general partner of OPI V, and OrbiMed Advisors LLC (\"Advisors\"), a registered adviser under the Investment Advisors Act of 1940, as amended, is the sole managing member of GP V. By virtue of such relationships, GP V and Advisors may be deemed to have voting and investment power with respect to the securities held by OPI V noted above and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"). Advisors exercised this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the Shares held by OPI V."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"This report on Form 4 is jointly filed by GP V and Advisors. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated a representative, currently Chau Khuong, an employee of Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act, or for any other purposes."}],"balance_after":1761956,"source":{"system":"sec-edgar","filing":"0000947871-19-000201","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787119000201/ownership.xml","form_type":"4"}},{"id":3732861,"issuer":{"id":1186,"kind":"organization","name":"Inspire Medical Systems, Inc.","symbol":"INSP"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":53130,"kind":"organization","name":"OrbiMed Capital GP V LLC","position":2,"cik":"0001615374","reported_name":"OrbiMed Capital GP V LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-12-13T21:35:46.000Z","date":"2018-12-11","kind":"sale","acquired":false,"shares":614772,"price":37.6,"value":23115427.2,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"These shares of the Issuer's common stock were sold in a block order at a price of $37.60."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by OrbiMed Private Investments V, LP (\"OPI V\"). OrbiMed Capital GP V LLC (\"GP V\") is the sole general partner of OPI V, and OrbiMed Advisors LLC (\"Advisors\"), a registered adviser under the Investment Advisors Act of 1940, as amended, is the sole managing member of GP V. By virtue of such relationships, GP V and Advisors may be deemed to have voting and investment power with respect to the securities held by OPI V noted above and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"). Advisors exercised this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the securities held by OPI V."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"This report on Form 4 is jointly filed by GP V and Advisors. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated a representative, currently Chau Khuong, an employee of Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act, or for any other purposes."}],"source":{"system":"sec-edgar","filing":"0000947871-18-000971","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787118000971/ownership.xml","form_type":"4"}},{"id":3786893,"issuer":{"id":2501,"kind":"organization","name":"SI-BONE, Inc.","symbol":"SIBN"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":53130,"kind":"organization","name":"OrbiMed Capital GP V LLC","position":2,"cik":"0001615374","reported_name":"OrbiMed Capital GP V LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series 7 Preferred Stock","published_at":"2018-10-19T20:52:36.000Z","date":"2018-10-19","kind":"exercise","acquired":false,"shares":179404,"ownership":{"direct":false,"nature":"By OrbiMed Private Investments V, LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"The Issuer's Series 7 Preferred Stock automatically converted into an equal number of shares of Issuer's common stock immediately upon the closing of the Issuer's initial public offering and has no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The Issuer's Series 7 Preferred Stock automatically converted into an equal number of shares of Issuer's common stock immediately upon the closing of the Issuer's initial public offering and has no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The Issuer's Series 7 Preferred Stock automatically converted into an equal number of shares of Issuer's common stock immediately upon the closing of the Issuer's initial public offering and has no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The Issuer's Series 7 Preferred Stock automatically converted into an equal number of shares of Issuer's common stock immediately upon the closing of the Issuer's initial public offering and has no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares held by OrbiMed Private Investments V, LP. (\"OPI V\"). OrbiMed Capital GP V LLC (\"GP V\") is the general partner of OPI V and OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the managing member of GP V. By virtue of such relationships, GP V and OrbiMed Advisors may be deemed to have voting and investment power with respect to the shares held by OPI V and as a result may be deemed to have have beneficial ownership of such shares. OrbiMed Advisors exercises investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein. David P. Bonita, a member of the Issuer's board of directors, is an employee of OrbiMed Advisors."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"This report on Form 4 is jointly filed by GP V and OrbiMed Advisors. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":179404},"source":{"system":"sec-edgar","filing":"0001209191-18-055701","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000120919118055701/doc4.xml","form_type":"4"}},{"id":3786892,"issuer":{"id":2501,"kind":"organization","name":"SI-BONE, Inc.","symbol":"SIBN"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":53130,"kind":"organization","name":"OrbiMed Capital GP V LLC","position":2,"cik":"0001615374","reported_name":"OrbiMed Capital GP V LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series 6 Preferred Stock","published_at":"2018-10-19T20:52:36.000Z","date":"2018-10-19","kind":"exercise","acquired":false,"shares":572326,"ownership":{"direct":false,"nature":"By OrbiMed Private Investments V, LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Issuer's Series 6 Preferred Stock automatically converted into approximately 1.05878 shares of Issuer's common stock immediately upon\nthe closing of the Issuer's initial public offering and has no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Issuer's Series 6 Preferred Stock automatically converted into approximately 1.05878 shares of Issuer's common stock immediately upon\nthe closing of the Issuer's initial public offering and has no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Issuer's Series 6 Preferred Stock automatically converted into approximately 1.05878 shares of Issuer's common stock immediately upon\nthe closing of the Issuer's initial public offering and has no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Issuer's Series 6 Preferred Stock automatically converted into approximately 1.05878 shares of Issuer's common stock immediately upon\nthe closing of the Issuer's initial public offering and has no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares held by OrbiMed Private Investments V, LP. (\"OPI V\"). OrbiMed Capital GP V LLC (\"GP V\") is the general partner of OPI V and OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the managing member of GP V. By virtue of such relationships, GP V and OrbiMed Advisors may be deemed to have voting and investment power with respect to the shares held by OPI V and as a result may be deemed to have have beneficial ownership of such shares. OrbiMed Advisors exercises investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein. David P. Bonita, a member of the Issuer's board of directors, is an employee of OrbiMed Advisors."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"This report on Form 4 is jointly filed by GP V and OrbiMed Advisors. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":605964},"source":{"system":"sec-edgar","filing":"0001209191-18-055701","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000120919118055701/doc4.xml","form_type":"4"}},{"id":3786891,"issuer":{"id":2501,"kind":"organization","name":"SI-BONE, Inc.","symbol":"SIBN"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":53130,"kind":"organization","name":"OrbiMed Capital GP V LLC","position":2,"cik":"0001615374","reported_name":"OrbiMed Capital GP V LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-10-19T20:52:36.000Z","date":"2018-10-19","kind":"purchase","acquired":true,"shares":200000,"price":15,"value":3000000.0,"ownership":{"direct":false,"nature":"By OrbiMed Private Investments V, LP"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares held by OrbiMed Private Investments V, LP. (\"OPI V\"). OrbiMed Capital GP V LLC (\"GP V\") is the general partner of OPI V and OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the managing member of GP V. By virtue of such relationships, GP V and OrbiMed Advisors may be deemed to have voting and investment power with respect to the shares held by OPI V and as a result may be deemed to have have beneficial ownership of such shares. OrbiMed Advisors exercises investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein. David P. Bonita, a member of the Issuer's board of directors, is an employee of OrbiMed Advisors."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"This report on Form 4 is jointly filed by GP V and OrbiMed Advisors. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":985368,"source":{"system":"sec-edgar","filing":"0001209191-18-055701","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000120919118055701/doc4.xml","form_type":"4"}},{"id":3786890,"issuer":{"id":2501,"kind":"organization","name":"SI-BONE, Inc.","symbol":"SIBN"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":53130,"kind":"organization","name":"OrbiMed Capital GP V LLC","position":2,"cik":"0001615374","reported_name":"OrbiMed Capital GP V LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-10-19T20:52:36.000Z","date":"2018-10-19","kind":"exercise","acquired":true,"shares":179404,"ownership":{"direct":false,"nature":"By OrbiMed Private Investments V, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The Issuer's Series 7 Preferred Stock automatically converted into an equal number of shares of Issuer's common stock immediately upon the closing of the Issuer's initial public offering and has no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares held by OrbiMed Private Investments V, LP. (\"OPI V\"). OrbiMed Capital GP V LLC (\"GP V\") is the general partner of OPI V and OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the managing member of GP V. By virtue of such relationships, GP V and OrbiMed Advisors may be deemed to have voting and investment power with respect to the shares held by OPI V and as a result may be deemed to have have beneficial ownership of such shares. OrbiMed Advisors exercises investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein. David P. Bonita, a member of the Issuer's board of directors, is an employee of OrbiMed Advisors."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"This report on Form 4 is jointly filed by GP V and OrbiMed Advisors. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":785368,"source":{"system":"sec-edgar","filing":"0001209191-18-055701","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000120919118055701/doc4.xml","form_type":"4"}},{"id":3786889,"issuer":{"id":2501,"kind":"organization","name":"SI-BONE, Inc.","symbol":"SIBN"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":53130,"kind":"organization","name":"OrbiMed Capital GP V LLC","position":2,"cik":"0001615374","reported_name":"OrbiMed Capital GP V LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-10-19T20:52:36.000Z","date":"2018-10-19","kind":"exercise","acquired":true,"shares":605964,"ownership":{"direct":false,"nature":"By OrbiMed Private Investments V, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Issuer's Series 6 Preferred Stock automatically converted into approximately 1.05878 shares of Issuer's common stock immediately upon\nthe closing of the Issuer's initial public offering and has no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares held by OrbiMed Private Investments V, LP. (\"OPI V\"). OrbiMed Capital GP V LLC (\"GP V\") is the general partner of OPI V and OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the managing member of GP V. By virtue of such relationships, GP V and OrbiMed Advisors may be deemed to have voting and investment power with respect to the shares held by OPI V and as a result may be deemed to have have beneficial ownership of such shares. OrbiMed Advisors exercises investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein. David P. Bonita, a member of the Issuer's board of directors, is an employee of OrbiMed Advisors."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"This report on Form 4 is jointly filed by GP V and OrbiMed Advisors. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":605964,"source":{"system":"sec-edgar","filing":"0001209191-18-055701","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000120919118055701/doc4.xml","form_type":"4"}},{"id":3879167,"issuer":{"id":122050,"kind":"organization","name":"Tricida, Inc.","symbol":"TCDA"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"ten_percent_owner":true}},{"id":53130,"kind":"organization","name":"OrbiMed Capital GP V LLC","position":2,"cik":"0001615374","reported_name":"OrbiMed Capital GP V LLC","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Series D Convertible Preferred Stock","published_at":"2018-07-03T01:11:42.000Z","date":"2018-07-02","kind":"exercise","acquired":false,"shares":4255319,"ownership":{"direct":false,"nature":"By OrbiMed Private Investments V, LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each of the Series A Convertible Preferred Stock, Series B Convertible Preferred Stock, Series C Convertible Preferred Stock and Series D Convertible Preferred Stock was convertible at any time at the option of the holder into Common Stock at a rate of 1/3.98, for no additional consideration, and had no expiration date.  Each of the Series A Convertible Preferred Stock, Series B Convertible Preferred Stock, Series C Convertible Preferred Stock and Series D Convertible Preferred Stock automatically converted into Common Stock, at a rate of 1/3.98 and for no additional consideration, upon closing of the Issuer's initial public offering of its Common Stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each of the Series A Convertible Preferred Stock, Series B Convertible Preferred Stock, Series C Convertible Preferred Stock and Series D Convertible Preferred Stock was convertible at any time at the option of the holder into Common Stock at a rate of 1/3.98, for no additional consideration, and had no expiration date.  Each of the Series A Convertible Preferred Stock, Series B Convertible Preferred Stock, Series C Convertible Preferred Stock and Series D Convertible Preferred Stock automatically converted into Common Stock, at a rate of 1/3.98 and for no additional consideration, upon closing of the Issuer's initial public offering of its Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each of the Series A Convertible Preferred Stock, Series B Convertible Preferred Stock, Series C Convertible Preferred Stock and Series D Convertible Preferred Stock was convertible at any time at the option of the holder into Common Stock at a rate of 1/3.98, for no additional consideration, and had no expiration date.  Each of the Series A Convertible Preferred Stock, Series B Convertible Preferred Stock, Series C Convertible Preferred Stock and Series D Convertible Preferred Stock automatically converted into Common Stock, at a rate of 1/3.98 and for no additional consideration, upon closing of the Issuer's initial public offering of its Common Stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each of the Series A Convertible Preferred Stock, Series B Convertible Preferred Stock, Series C Convertible Preferred Stock and Series D Convertible Preferred Stock was convertible at any time at the option of the holder into Common Stock at a rate of 1/3.98, for no additional consideration, and had no expiration date.  Each of the Series A Convertible Preferred Stock, Series B Convertible Preferred Stock, Series C Convertible Preferred Stock and Series D Convertible Preferred Stock automatically converted into Common Stock, at a rate of 1/3.98 and for no additional consideration, upon closing of the Issuer's initial public offering of its Common Stock."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These securities are held of record by OrbiMed Private Investments V, LP (\"OPI V\").  OrbiMed Capital GP V LLC (\"GP V\") is the sole general partner of OPI V, and OrbiMed Advisors LLC (\"Advisors\"), a registered adviser under the Investment Advisors Act of 1940, as amended, is the sole managing member of GP V.  By virtue of such relationships, GP V and Advisors may be deemed to have voting and investment power with respect to the securities held by OPI V noted above and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\").  Advisors exercised this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the Shares held by OPI V."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by OrbiMed Private Investments V, LP (\"OPI V\").  OrbiMed Capital GP V LLC (\"GP V\") is the sole general partner of OPI V, and OrbiMed Advisors LLC (\"Advisors\"), a registered adviser under the Investment Advisors Act of 1940, as amended, is the sole managing member of GP V.  By virtue of such relationships, GP V and Advisors may be deemed to have voting and investment power with respect to the securities held by OPI V noted above and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\").  Advisors exercised this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the Shares held by OPI V."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"This report on Form 4 is jointly filed by GP V and Advisors.  Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its pecuniary interest therein, if any.  The Reporting Persons have designated a representative, David P. Bonita, an employee of Advisors, to serve on the Company's board of directors.  This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act, or for any other purposes."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1069175},"source":{"system":"sec-edgar","filing":"0001140361-18-031065","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000114036118031065/form4.xml","form_type":"4"}},{"id":3879166,"issuer":{"id":122050,"kind":"organization","name":"Tricida, Inc.","symbol":"TCDA"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"ten_percent_owner":true}},{"id":53130,"kind":"organization","name":"OrbiMed Capital GP V LLC","position":2,"cik":"0001615374","reported_name":"OrbiMed Capital GP V LLC","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Series C Convertible Preferred Stock","published_at":"2018-07-03T01:11:42.000Z","date":"2018-07-02","kind":"exercise","acquired":false,"shares":14292958,"ownership":{"direct":false,"nature":"By OrbiMed Private Investments V, LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each of the Series A Convertible Preferred Stock, Series B Convertible Preferred Stock, Series C Convertible Preferred Stock and Series D Convertible Preferred Stock was convertible at any time at the option of the holder into Common Stock at a rate of 1/3.98, for no additional consideration, and had no expiration date.  Each of the Series A Convertible Preferred Stock, Series B Convertible Preferred Stock, Series C Convertible Preferred Stock and Series D Convertible Preferred Stock automatically converted into Common Stock, at a rate of 1/3.98 and for no additional consideration, upon closing of the Issuer's initial public offering of its Common Stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each of the Series A Convertible Preferred Stock, Series B Convertible Preferred Stock, Series C Convertible Preferred Stock and Series D Convertible Preferred Stock was convertible at any time at the option of the holder into Common Stock at a rate of 1/3.98, for no additional consideration, and had no expiration date.  Each of the Series A Convertible Preferred Stock, Series B Convertible Preferred Stock, Series C Convertible Preferred Stock and Series D Convertible Preferred Stock automatically converted into Common Stock, at a rate of 1/3.98 and for no additional consideration, upon closing of the Issuer's initial public offering of its Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each of the Series A Convertible Preferred Stock, Series B Convertible Preferred Stock, Series C Convertible Preferred Stock and Series D Convertible Preferred Stock was convertible at any time at the option of the holder into Common Stock at a rate of 1/3.98, for no additional consideration, and had no expiration date.  Each of the Series A Convertible Preferred Stock, Series B Convertible Preferred Stock, Series C Convertible Preferred Stock and Series D Convertible Preferred Stock automatically converted into Common Stock, at a rate of 1/3.98 and for no additional consideration, upon closing of the Issuer's initial public offering of its Common Stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each of the Series A Convertible Preferred Stock, Series B Convertible Preferred Stock, Series C Convertible Preferred Stock and Series D Convertible Preferred Stock was convertible at any time at the option of the holder into Common Stock at a rate of 1/3.98, for no additional consideration, and had no expiration date.  Each of the Series A Convertible Preferred Stock, Series B Convertible Preferred Stock, Series C Convertible Preferred Stock and Series D Convertible Preferred Stock automatically converted into Common Stock, at a rate of 1/3.98 and for no additional consideration, upon closing of the Issuer's initial public offering of its Common Stock."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These securities are held of record by OrbiMed Private Investments V, LP (\"OPI V\").  OrbiMed Capital GP V LLC (\"GP V\") is the sole general partner of OPI V, and OrbiMed Advisors LLC (\"Advisors\"), a registered adviser under the Investment Advisors Act of 1940, as amended, is the sole managing member of GP V.  By virtue of such relationships, GP V and Advisors may be deemed to have voting and investment power with respect to the securities held by OPI V noted above and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\").  Advisors exercised this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the Shares held by OPI V."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by OrbiMed Private Investments V, LP (\"OPI V\").  OrbiMed Capital GP V LLC (\"GP V\") is the sole general partner of OPI V, and OrbiMed Advisors LLC (\"Advisors\"), a registered adviser under the Investment Advisors Act of 1940, as amended, is the sole managing member of GP V.  By virtue of such relationships, GP V and Advisors may be deemed to have voting and investment power with respect to the securities held by OPI V noted above and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\").  Advisors exercised this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the Shares held by OPI V."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"This report on Form 4 is jointly filed by GP V and Advisors.  Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its pecuniary interest therein, if any.  The Reporting Persons have designated a representative, David P. Bonita, an employee of Advisors, to serve on the Company's board of directors.  This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act, or for any other purposes."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":3591194},"source":{"system":"sec-edgar","filing":"0001140361-18-031065","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000114036118031065/form4.xml","form_type":"4"}},{"id":3879165,"issuer":{"id":122050,"kind":"organization","name":"Tricida, Inc.","symbol":"TCDA"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"ten_percent_owner":true}},{"id":53130,"kind":"organization","name":"OrbiMed Capital GP V LLC","position":2,"cik":"0001615374","reported_name":"OrbiMed Capital GP V LLC","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Series B Convertible Preferred Stock","published_at":"2018-07-03T01:11:42.000Z","date":"2018-07-02","kind":"exercise","acquired":false,"shares":17117085,"ownership":{"direct":false,"nature":"By OrbiMed Private Investments V, LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each of the Series A Convertible Preferred Stock, Series B Convertible Preferred Stock, Series C Convertible Preferred Stock and Series D Convertible Preferred Stock was convertible at any time at the option of the holder into Common Stock at a rate of 1/3.98, for no additional consideration, and had no expiration date.  Each of the Series A Convertible Preferred Stock, Series B Convertible Preferred Stock, Series C Convertible Preferred Stock and Series D Convertible Preferred Stock automatically converted into Common Stock, at a rate of 1/3.98 and for no additional consideration, upon closing of the Issuer's initial public offering of its Common Stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each of the Series A Convertible Preferred Stock, Series B Convertible Preferred Stock, Series C Convertible Preferred Stock and Series D Convertible Preferred Stock was convertible at any time at the option of the holder into Common Stock at a rate of 1/3.98, for no additional consideration, and had no expiration date.  Each of the Series A Convertible Preferred Stock, Series B Convertible Preferred Stock, Series C Convertible Preferred Stock and Series D Convertible Preferred Stock automatically converted into Common Stock, at a rate of 1/3.98 and for no additional consideration, upon closing of the Issuer's initial public offering of its Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each of the Series A Convertible Preferred Stock, Series B Convertible Preferred Stock, Series C Convertible Preferred Stock and Series D Convertible Preferred Stock was convertible at any time at the option of the holder into Common Stock at a rate of 1/3.98, for no additional consideration, and had no expiration date.  Each of the Series A Convertible Preferred Stock, Series B Convertible Preferred Stock, Series C Convertible Preferred Stock and Series D Convertible Preferred Stock automatically converted into Common Stock, at a rate of 1/3.98 and for no additional consideration, upon closing of the Issuer's initial public offering of its Common Stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each of the Series A Convertible Preferred Stock, Series B Convertible Preferred Stock, Series C Convertible Preferred Stock and Series D Convertible Preferred Stock was convertible at any time at the option of the holder into Common Stock at a rate of 1/3.98, for no additional consideration, and had no expiration date.  Each of the Series A Convertible Preferred Stock, Series B Convertible Preferred Stock, Series C Convertible Preferred Stock and Series D Convertible Preferred Stock automatically converted into Common Stock, at a rate of 1/3.98 and for no additional consideration, upon closing of the Issuer's initial public offering of its Common Stock."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These securities are held of record by OrbiMed Private Investments V, LP (\"OPI V\").  OrbiMed Capital GP V LLC (\"GP V\") is the sole general partner of OPI V, and OrbiMed Advisors LLC (\"Advisors\"), a registered adviser under the Investment Advisors Act of 1940, as amended, is the sole managing member of GP V.  By virtue of such relationships, GP V and Advisors may be deemed to have voting and investment power with respect to the securities held by OPI V noted above and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\").  Advisors exercised this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the Shares held by OPI V."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by OrbiMed Private Investments V, LP (\"OPI V\").  OrbiMed Capital GP V LLC (\"GP V\") is the sole general partner of OPI V, and OrbiMed Advisors LLC (\"Advisors\"), a registered adviser under the Investment Advisors Act of 1940, as amended, is the sole managing member of GP V.  By virtue of such relationships, GP V and Advisors may be deemed to have voting and investment power with respect to the securities held by OPI V noted above and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\").  Advisors exercised this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the Shares held by OPI V."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"This report on Form 4 is jointly filed by GP V and Advisors.  Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its pecuniary interest therein, if any.  The Reporting Persons have designated a representative, David P. Bonita, an employee of Advisors, to serve on the Company's board of directors.  This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act, or for any other purposes."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":4300774},"source":{"system":"sec-edgar","filing":"0001140361-18-031065","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000114036118031065/form4.xml","form_type":"4"}},{"id":3879164,"issuer":{"id":122050,"kind":"organization","name":"Tricida, Inc.","symbol":"TCDA"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"ten_percent_owner":true}},{"id":53130,"kind":"organization","name":"OrbiMed Capital GP V LLC","position":2,"cik":"0001615374","reported_name":"OrbiMed Capital GP V LLC","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Series A Convertible Preferred Stock","published_at":"2018-07-03T01:11:42.000Z","date":"2018-07-02","kind":"exercise","acquired":false,"shares":6207674,"ownership":{"direct":false,"nature":"By OrbiMed Private Investments V, LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each of the Series A Convertible Preferred Stock, Series B Convertible Preferred Stock, Series C Convertible Preferred Stock and Series D Convertible Preferred Stock was convertible at any time at the option of the holder into Common Stock at a rate of 1/3.98, for no additional consideration, and had no expiration date.  Each of the Series A Convertible Preferred Stock, Series B Convertible Preferred Stock, Series C Convertible Preferred Stock and Series D Convertible Preferred Stock automatically converted into Common Stock, at a rate of 1/3.98 and for no additional consideration, upon closing of the Issuer's initial public offering of its Common Stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each of the Series A Convertible Preferred Stock, Series B Convertible Preferred Stock, Series C Convertible Preferred Stock and Series D Convertible Preferred Stock was convertible at any time at the option of the holder into Common Stock at a rate of 1/3.98, for no additional consideration, and had no expiration date.  Each of the Series A Convertible Preferred Stock, Series B Convertible Preferred Stock, Series C Convertible Preferred Stock and Series D Convertible Preferred Stock automatically converted into Common Stock, at a rate of 1/3.98 and for no additional consideration, upon closing of the Issuer's initial public offering of its Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each of the Series A Convertible Preferred Stock, Series B Convertible Preferred Stock, Series C Convertible Preferred Stock and Series D Convertible Preferred Stock was convertible at any time at the option of the holder into Common Stock at a rate of 1/3.98, for no additional consideration, and had no expiration date.  Each of the Series A Convertible Preferred Stock, Series B Convertible Preferred Stock, Series C Convertible Preferred Stock and Series D Convertible Preferred Stock automatically converted into Common Stock, at a rate of 1/3.98 and for no additional consideration, upon closing of the Issuer's initial public offering of its Common Stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each of the Series A Convertible Preferred Stock, Series B Convertible Preferred Stock, Series C Convertible Preferred Stock and Series D Convertible Preferred Stock was convertible at any time at the option of the holder into Common Stock at a rate of 1/3.98, for no additional consideration, and had no expiration date.  Each of the Series A Convertible Preferred Stock, Series B Convertible Preferred Stock, Series C Convertible Preferred Stock and Series D Convertible Preferred Stock automatically converted into Common Stock, at a rate of 1/3.98 and for no additional consideration, upon closing of the Issuer's initial public offering of its Common Stock."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These securities are held of record by OrbiMed Private Investments V, LP (\"OPI V\").  OrbiMed Capital GP V LLC (\"GP V\") is the sole general partner of OPI V, and OrbiMed Advisors LLC (\"Advisors\"), a registered adviser under the Investment Advisors Act of 1940, as amended, is the sole managing member of GP V.  By virtue of such relationships, GP V and Advisors may be deemed to have voting and investment power with respect to the securities held by OPI V noted above and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\").  Advisors exercised this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the Shares held by OPI V."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by OrbiMed Private Investments V, LP (\"OPI V\").  OrbiMed Capital GP V LLC (\"GP V\") is the sole general partner of OPI V, and OrbiMed Advisors LLC (\"Advisors\"), a registered adviser under the Investment Advisors Act of 1940, as amended, is the sole managing member of GP V.  By virtue of such relationships, GP V and Advisors may be deemed to have voting and investment power with respect to the securities held by OPI V noted above and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\").  Advisors exercised this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the Shares held by OPI V."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"This report on Form 4 is jointly filed by GP V and Advisors.  Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its pecuniary interest therein, if any.  The Reporting Persons have designated a representative, David P. Bonita, an employee of Advisors, to serve on the Company's board of directors.  This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act, or for any other purposes."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1559716},"source":{"system":"sec-edgar","filing":"0001140361-18-031065","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000114036118031065/form4.xml","form_type":"4"}}],"next_cursor":"2018-07-03T01:11:42.000000Z,3879164"}